FIND

researchers

DISCOVER

relevant articles

PROMOTE

your research

now for free

Dirk Schadendorf

Research Profile

Disorders

Chemicals & Drugs

Anatomy

Physiology

Concepts & Ideas

Procedures

Living Beings

Young Adult

Co-author Network

Publications

TOP 3
Alexandra Sevko; Ludmila Umansky; Michal Baniyash; Christine S Falk; Julia Kanterman; Masashi Kato; Tillmann Michels; Marcel Ramacher; Moshe Sade-Feldman; Dirk Schadendorf; Viktor Umansky
Cyclophosphamide promotes chronic inflammation-dependent immunosuppression and prevents antitumor response in melanoma.
Caroline Robert; Dirk Schadendorf; F Stephen Hodi; Marianne Messina; Steven O'Day
Efficacy and safety of retreatment with ipilimumab in patients with pretreated advanced melanoma who progressed after initially achieving disease control.
Paolo A Ascierto; J Thaddeus Beck; Carola Berking; Christian U Blank; Sanjiv S Agarwala; Axel Hauschild; Faiz Niazi; Malte Peters; Paola Queirolo; Dirk Schadendorf; Annie St-Pierre; Carla Ml van Herpen; Simon Wandel; Angela Zubel; Reinhard Dummer
MEK162 for patients with advanced melanoma harbouring NRAS or Val600 BRAF mutations: a non-randomised, open-label phase 2 study.

Register for free to view:

Visualized networks:

See your personal network in
sophisticated graphical views

GeoTargeted Searches:

Locate experts around the world
and connect with global collaborators

Research Profiles:

See the research activity
of experts around the globe

Geonetwork of Dirk Schadendorf (preview)

Cities where this author has publications
Cities where co-authors of this author have publications

Flash Player Required

All Publications

2013: Alexandra Sevko; Ludmila Umansky; Michal Baniyash; Christine S Falk; Julia Kanterman; Masashi Kato; Tillmann Michels; Marcel Ramacher; Moshe Sade-Feldman; Dirk Schadendorf; Viktor Umansky
Cyclophosphamide promotes chronic inflammation-dependent immunosuppression and prevents antitumor response in melanoma.
The Journal of investigative dermatology 2013;133(6):1610-9.
2013: Caroline Robert; Dirk Schadendorf; F Stephen Hodi; Marianne Messina; Steven O'Day
Efficacy and safety of retreatment with ipilimumab in patients with pretreated advanced melanoma who progressed after initially achieving disease control.
Clinical cancer research : an official journal of the American Association for Cancer Research 2013;19(8):2232-9.
2013: Paolo A Ascierto; J Thaddeus Beck; Carola Berking; Christian U Blank; Sanjiv S Agarwala; Axel Hauschild; Faiz Niazi; Malte Peters; Paola Queirolo; Dirk Schadendorf; Annie St-Pierre; Carla Ml van Herpen; Simon Wandel; Angela Zubel; Reinhard Dummer
MEK162 for patients with advanced melanoma harbouring NRAS or Val600 BRAF mutations: a non-randomised, open-label phase 2 study.
The lancet oncology 2013;14(3):249-56.
2013: Klaus G Griewank; Dirk Schadendorf; Selma Ugurel; Annette Paschen
New developments in biomarkers for melanoma.
Current opinion in oncology 2013;25(2):145-51.
2013: Steven R Whittaker; Glenn S Cowley; Jessica Hsiao; David E Root; Dirk Schadendorf; Jean-Philippe Theurillat; Eliezer Van Allen; Nikhil Wagle; Levi A Garraway
A genome-scale RNA interference screen implicates NF1 loss in resistance to RAF inhibition.
Cancer discovery 2013;3(3):350-62.
2013: Chonglin Luo; Patrick R Merz; Dirk Schadendorf; Birgit Schittek; Tobias Sinnberg; Paul W Tetteh; Alia Abukiwan; Elke Dickes; Sven Diederichs; Stefan Holland-Cunz; Agnes Hotz-Wagenblatt; Stefan B Eichmüller
miR-137 inhibits the invasion of melanoma cells through downregulation of multiple oncogenic target genes.
The Journal of investigative dermatology 2013;133(3):768-75.
2013: Stefan Esser; Götz Gelbrich; Alexander Goehler; Till Neumann; Norbert Brockmeyer; Raimund Erbel; Dirk Schadendorf; Nico Reinsch
Prevalence of cardiovascular diseases in HIV-infected outpatients: results from a prospective, multicenter cohort study.
Clinical research in cardiology : official journal of the German Cardiac Society 2013;102(3):203-13.
2013: Susanne Horn; Stephanie Kadel; Adina Figl; Christine Fischer; Andreas Gast; Kari Hemminki; Iris Moll; Eduardo Nagore; Sivaramakrishna Rachakonda; Dirk Schadendorf; Antje Sucker; Rajiv Kumar
TERT promoter mutations in familial and sporadic melanoma.
Science (New York, N.Y.) 2013;339(6122):959-61.
2013: Daniela Beck; Tilo Biedermann; Christian Busch; Stefan Drießen; Jürgen Eberle; Keith Flaherty; Claus Garbe; Juan Lucio Iovanna; Dagmar Kulms; Konstantinos G Lasithiotakis; Heike Niessner; Kim H T Paraiso; Dirk Schadendorf; Martin Schaller; Birgit Schittek; Tobias Sinnberg; Keiran S M Smalley; Björn Stork; Sophie Vasseur; Benjamin Weide; Sebastian Wesselborg; Jürgen Bauer; Friedegund Meier
Vemurafenib potently induces endoplasmic reticulum stress-mediated apoptosis in BRAFV600E melanoma cells.
Science signaling 2013;6(260):ra7.
2013: Mario Lacouture; Richard J Lee; Christopher J McCormack; Patricia L Myskowski; Betty Nelson; Keith B Nolop; Victor G Prieto; Caroline Robert; Dirk Schadendorf; Olivia Spleiss; Fei Su; James L Troy; Kerstin Trunzer; Madeleine Duvic; Joseph F Grippo; Axel Hauschild; Caroline C Kim; Matthew J Klimek; Andrew K Joe
Analysis of dermatologic events in vemurafenib-treated patients with melanoma.
The oncologist 2013;18(3):314-22.
2013: Sonali Pechlivanis; Dirk Schadendorf; André Scherag; Raimund Erbel; Per Hoffmann; Karl-Heinz Jöckel; Susanne Moebus; Stefan Möhlenkamp; Thomas W Mühleisen; Markus M Nöthen
Risk loci for coronary artery calcification replicated at 9p21 and 6q24 in the Heinz Nixdorf Recall Study.
BMC medical genetics 2013;14():23.
2013: E H J G Aarntzen; Gosse J Adema; Willeke A M Blokx; Kalijn Bol; Alexandra J Croockewit; I Jolanda M De Vries; Johannes H W de Wilt; John B A G Haanen; J F M Jacobs; William W Kwok; W Joost Lesterhuis; Roel Mus; Cornelis J A Punt; Dirk Schadendorf; Gerty Schreibelt; Danita Schuurhuis; Michelle M van Rossum; Carl G Figdor
Targeting CD4(+) T-helper cells improves the induction of antitumor responses in dendritic cell-based vaccination.
Cancer research 2013;73(1):19-29.
2012: Matthias Preusser; Dirk Schadendorf; Anna S Berghoff; Nancy U Lin; Roger Stupp
Brain metastasis: opportunity for drug development?
Current opinion in neurology 2012;25(6):786-94.
2012: L Zimmer; J Vaubel; Dirk Schadendorf
[Immunotherapy of melanomas].
Der Hautarzt; Zeitschrift für Dermatologie, Venerologie, und verwandte Gebiete 2012;63(12):952-8.
2012: Matthias Preusser; Jaap C Reijneveld; Dirk Schadendorf; Riccardo Soffietti; Jörg-Christian Tonn; Frank Winkler; Brigitta Baumert; Yazid Belkacemi; Anna Sophie Berghoff; David A Cameron; Laurence Collette; Renata Duchnowska; Sven Haller; Jacek Jassem; Martin Klein; Nancy Lin; Sandrine Marreaud; Paula Mulvenna; Damien C Weber
Trial design on prophylaxis and treatment of brain metastases: lessons learned from the EORTC Brain Metastases Strategic Meeting 2012.
European journal of cancer (Oxford, England : 1990) 2012;48(18):3439-47.
2012: Guangxu Ren; Dirk Schadendorf; Joerg F Schlaak; Ulf Dittmer; Stefan Esser; Guido Gerken; Christoph Jochum; Gang Wu; Zhenghong Yuan; Joerg Timm
Interleukin 21 augments the hepatitis B virus-specific CD8+ T-cell response in vitro in patients coinfected with HIV-1.
AIDS (London, England) 2012;26(17):2145-53.
2012: Georgina V Long; Anne-Marie Martin; Laurent Mortier; Igor Puzanov; Caroline Robert; Michael Streit; Suzanne Swann; Julie Switzky; Hussein Tawbi; Uwe Trefzer; Tabea Wilhelm; Lisa Zimmer; Alain Algazi; Paolo A Ascierto; Paul B Chapman; Michael A Davies; Vicki Goodman; Mary Guckert; Axel Hauschild; Richard F Kefford; John M Kirkwood; Dirk Schadendorf
Dabrafenib in patients with Val600Glu or Val600Lys BRAF-mutant melanoma metastatic to the brain (BREAK-MB): a multicentre, open-label, phase 2 trial.
The lancet oncology 2012;13(11):1087-95.
2012: Alexander M M Eggermont; Gaetan de Schaetzen; Reinhard Dummer; Wim H J Kruit; Jeremy Marsden; Poulam M Patel; Cornelis J A Punt; Caroline Robert; François Salès; mario santinami; Dirk Schadendorf; Alan Spatz; Stefan Suciu; Alessandro Testori; Ulrich Keilholz
Long-term results of the randomized phase III trial EORTC 18991 of adjuvant therapy with pegylated interferon alfa-2b versus observation in resected stage III melanoma.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2012;30(31):3810-8.
2012: Wiebke Hansen; Simone Abel; Juliane Albert; Christina Alter; Jan Buer; Marina Hutzler; Stefanie Kliche; Shimon Sakaguchi; Dirk Schadendorf; Tim D. Sparwasser; Christian Stockmann; Astrid M Westendorf; Iris Helfrich
Neuropilin 1 deficiency on CD4+Foxp3+ regulatory T cells impairs mouse melanoma growth.
The Journal of experimental medicine 2012;209(11):2001-16.
2012: D Matusiewicz; Dirk Schadendorf; J Wasem; Andreas Körber; A Neumann
[Psoriasis in children and adolescents. A nationwide physician survey on the healthcare situation in Germany].
Der Hautarzt; Zeitschrift für Dermatologie, Venerologie, und verwandte Gebiete 2012;63(10):801-7.
2012: Nadine A Kasparian; Sancy A Leachman; Julia Newton-Bishop; Jane Palmer; Barbara Peric; Dace Pjanova; Susana Puig; Dirk Schadendorf; Aad Tibben; Paul Affleck; Lisa G Aspinwall; Esther Azizi; Orna Baron-Epel; Linda Battistuzzi; Wilma Bergman; Yvonne Brandberg; Richard Bränström; William Bruno; May Chan; Yu-mei Chang; Francisco Cuellar; Tadeusz Debniak; Slawomir Ertmanski; Adina Figl; Melinda Gonzalez; Nelleke A Gruis; Nicholas K Hayward; Olita Heisele; Marko Hocevar; Peter Kanetsky
Skin examination behavior: the role of melanoma history, skin type, psychosocial factors, and region of residence in determining clinical and self-conducted skin examination.
Archives of dermatology 2012;148(10):1142-51.
2012: Ingo Stoffels; Christian Boy; Joachim Dissemond; Kerstin Klötgen; Jasna Kuhn; Thorsten Pöppel; Dirk Schadendorf; Joachim Klode
Association between sentinel lymph node excision with or without preoperative SPECT/CT and metastatic node detection and disease-free survival in melanoma.
JAMA : the journal of the American Medical Association 2012;308(10):1007-14.
2012: Dirk Schadendorf; J Vaubel; E Livingstone; L Zimmer
Advances and perspectives in immunotherapy of melanoma.
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 2012;23 Suppl 10():x104-8.
2012: Sabrina Urban; Fang Zhao; Kathrin Textoris-Taube; Helga Bernhard; Sandrine Cadel; Tanja Dannenberg; Frédéric Ebstein; Thierry Foulon; Anne Halenius; Peter Henklein; Katharina Janek; Jan H Kessler; Ferry Ossendorp; Annette Paschen; Julia Paschke; Barbara Reimann; Dirk Schadendorf; Christin Seifert; Ulrike Seifert
The efficiency of human cytomegalovirus pp65(495-503) CD8+ T cell epitope generation is determined by the balanced activities of cytosolic and endoplasmic reticulum-resident peptidases.
Journal of immunology (Baltimore, Md. : 1950) 2012;189(2):529-38.
2012: Keith T Flaherty; Claus Garbe; Jessica C Hassel; Peter Hersey; James M G Larkin; Anne-Marie Martin; Mark R Middleton; Mohammed Milhem; Peter Mohr; Paul Nathan; Marta Nyakas; Daniele Ouellet; Kiran Patel; Caroline Robert; Piotr Rutkowski; Dirk Schadendorf; Laurie J Sherman; Uwe Trefzer; Jochen Utikal; Frank S Wu; Jürgen C Becker; Michelle Casey; Lev V Demidov; Brigitte Dreno; Reinhard Dummer
Improved survival with MEK inhibition in BRAF-mutated melanoma.
The New England journal of medicine 2012;367(2):107-14.
2012: Lisa Zimmer; André Scherag; Antje Sucker; Klaus Busam; Richard D Carvajal; Reinhard Dummer; Friederike Egberts; Simone M Goldinger; Axel Hauschild; Uwe Hillen; Mohammed Kashani-Sabet; Mario E Lacouture; Elisabeth Livingstone; Georgina V Long; Grant McArthur; Dirk Schadendorf
Atypical melanocytic proliferations and new primary melanomas in patients with advanced melanoma undergoing selective BRAF inhibition.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2012;30(19):2375-83.
2012: Lisa Zimmer; Julia Vaubel; Elisabeth Livingstone; Dirk Schadendorf
Side effects of systemic oncological therapies in dermatology.
Journal der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : JDDG 2012;10(7):475-86.
2012: Stefan Esser; Falko M Heinemann; Peter A Horn; Robert Jablonka; Hans Jaeger; Stefan Reuter; Dirk Schadendorf; Pia Schenk-Westkamp; Ariane von Krosigk; Monika Lindemann
Detection of abacavir hypersensitivity by ELISpot method.
Inflammation & allergy drug targets 2012;11(3):227-34.
2012: Benjamin Weide; Henning Zelba; Annette Pflugfelder; Dirk Schadendorf; Antje Sucker; Erik H J G Aarntzen; Petra Büttner; I Jolanda M De Vries; Evelyna Derhovanessian; Anna Maria Di Giacomo; Thomas K Eigentler; Claus Garbe; Michele Maio; Graham Pawelec
Functional T cells targeting NY-ESO-1 or Melan-A are predictive for survival of patients with distant melanoma metastasis.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2012;30(15):1835-41.
2012: Elisabeth Livingstone; Julia Vaubel; Lisa Zimmer; Dirk Schadendorf
Current advances and perspectives in the treatment of advanced melanoma.
Journal der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : JDDG 2012;10(5):319-25.
2012: John R Davies; Zaida García-Casado; Paola Ghiorzo; Nelleke A Gruis; Johan Hansson; Mark Harland; Veronica Höiom; Peter Kanetsky; Kairen Kukalizch; Rajiv Kumar; Srinivasan Madhusudan; Eduardo Nagore; Zighereda Ogbah; Ichiro Okamoto; Aija Ozola; Dace Pjanova; Susana Puig; Paola Queirolo; Juliette A Randerson-Moor; philippe saiag; Dirk Schadendorf; Nadem Soufir; Antje Sucker; Remco van Doorn; Judith Wendt; Paul Affleck; Jennifer H Barrett; D Timothy Bishop; Julia Newton-Bishop
Inherited variants in the MC1R gene and survival from cutaneous melanoma: a BioGenoMEL study.
Pigment cell & melanoma research 2012;25(3):384-94.
2012: Tobias T Schimming; Antje Sucker; Nicola Bielefeld; Florian Grabellus; Iris Moll; Sonali Pechlivanis; Mathias Roner; Dirk Schadendorf; Uwe Hillen
pHH3 immunostaining improves interobserver agreement of mitotic index in thin melanomas.
The American Journal of dermatopathology 2012;34(3):266-9.
2012: Romina E Lenci; P Sivaramakrishna Rachakonda; Dirk Schadendorf; Antje Sucker; Alexander N R Weber; Andreas Brandt; Andreas Gast; Kari Hemminki; Andriy V Kubarenko; Rajiv Kumar
Integrin genes and susceptibility to human melanoma.
Mutagenesis 2012;27(3):367-73.
2012: Lisa Zimmer; Arne Becker; Stephanie Dömkes; Uwe Hillen; Elisabeth Livingstone; Dirk Schadendorf
Panniculitis with arthralgia in patients with melanoma treated with selective BRAF inhibitors and its management.
Archives of dermatology 2012;148(3):357-61.
2012: I Stoffels; F Wichmann; C Boy; Joachim Dissemond; S Mueller; T Poeppel; S Rosenbaum-Krumme; Dirk Schadendorf; Joachim Klode
Radio-guided surgery: advantages of a new portable γ-camera (Sentinella) for intraoperative real time imaging and detection of sentinel lymph nodes in cutaneous malignancies.
Journal of the European Academy of Dermatology and Venereology : JEADV 2012;26(3):308-13.
2012: Philipp M Amann; Stefan B Eichmüller; Muriel Freudenberger; Claudia Hofmann; Chonglin Luo; Robert W Owen; Dirk Schadendorf; Alexandr V Bazhin
Vitamin A metabolism in benign and malignant melanocytic skin cells: importance of lecithin/retinol acyltransferase and RPE65.
Journal of cellular physiology 2012;227(2):718-28.
2012: I Stoffels; Joachim Dissemond; Uwe Hillen; Dirk Schadendorf; A Schulz; Joachim Klode
Reliability and cost-effectiveness of complete lymph node dissection under tumescent local anaesthesia vs. general anaesthesia: a retrospective analysis in patients with malignant melanoma AJCC stage III.
Journal of the European Academy of Dermatology and Venereology : JEADV 2012;26(2):200-6.
2012: Patrick A Oberholzer; Emanuele Palescandolo; Adriano Piris; Caroline Robert; Christine Roden; Dirk Schadendorf; Antje Sucker; Kristin Ardlie; Clinton J Chalk; Piotr Dziunycz; Günther Hofbauer; Robert Jones; Nyam Kamsukom; Damien Kee; Laura E MacConaill; Grant A McArthur; Levi A Garraway
RAS mutations are associated with the development of cutaneous squamous cell tumors in patients treated with RAF inhibitors.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2012;30(3):316-21.
2012: Anja Heinemann; Sven Diederichs; Jürgen Eberle; Sonali Pechlivanis; Dirk Schadendorf; Alexander Steinle; Fang Zhao; Annette Paschen
Tumor suppressive microRNAs miR-34a/c control cancer cell expression of ULBP2, a stress-induced ligand of the natural killer cell receptor NKG2D.
Cancer research 2012;72(2):460-71.
2012: Romina Elizabeth Lenci; Iris Moll; Eduardo Nagore; Dolores Planelles; Celia Requena; Dirk Schadendorf; Antje Sucker; Justo Lorenzo Bermejo; Melanie Bevier; Andreas Brandt; Kari Hemminki; Rajiv Kumar
Influence of genetic variants in type I interferon genes on melanoma survival and therapy.
PloS one 2012;7(11):e50692.
2012: Axel Hauschild; Oliver Kölbl; Andreas Mackensen; Dirk Schadendorf
[Foreword].
Onkologie 2012;35 Suppl 2():1.
2011: Maja A Hofmann; Martin Kaatz; Peter Mohr; Dirk Schadendorf; Wolfgang Tilgen; Uwe Trefzer; Ulrike Drecoll; Claus Garbe; Axel Hauschild; Michael Weichenthal; Jens Ulrich
Prospective evaluation of supportive care with or without CVD chemotherapy as a second-line treatment in advanced melanoma by patient's choice: a multicentre Dermatologic Cooperative Oncology Group trial.
Melanoma research 2011;21(6):516-23.
2011: Giorgios Papaspyrou; Dirk Schadendorf; Jochen A Werner; Claus Garbe; Axel Hauschild; Friederike Egberts
Mucosal melanomas of the head and neck: new aspects of the clinical outcome, molecular pathology, and treatment with c-kit inhibitors.
Melanoma research 2011;21(6):475-82.
2011: Christiane Meyer; Wolfram Osen; Marcel Ramacher; Dirk Schadendorf; Alexandra Sevko; Michal Baniyash; Alexandr V Bazhin; Ivan Borrello; Christine S Falk; Masashi Kato; Viktor Umansky
Chronic inflammation promotes myeloid-derived suppressor cell activation blocking antitumor immunity in transgenic mouse melanoma model.
Proceedings of the National Academy of Sciences of the United States of America 2011;108(41):17111-6.
2011: Khelifa Arab; Rainer Claus; Allan V Espinosa; Andreas Gast; Thomas Hielscher; Joseph Po-Hsien Huang; Rajiv Kumar; Carl D Morrison; Matthew D Ringel; Dirk Schadendorf; Laura T Smith; Dieter Weichenhan; Christoph Plass
Epigenetic deregulation of TCF21 inhibits metastasis suppressor KISS1 in metastatic melanoma.
Carcinogenesis 2011;32(10):1467-73.
2011: Johanna Christina Czeschik; Lisa Huptas; Dirk Schadendorf; Uwe Hillen
Nodular scabies: hypersensitivity reaction or infection?
Journal der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : JDDG 2011;9(10):840-1.
2011: Joachim Klode; Andreas Körber; S Mueller; T Poeppel; Dirk Schadendorf; I Stoffels; C Boy; Joachim Dissemond
Advantages of preoperative hybrid SPECT/CT in detection of sentinel lymph nodes in cutaneous head and neck malignancies.
Journal of the European Academy of Dermatology and Venereology : JEADV 2011;25(10):1213-21.
2011: Elisabeth Livingstone; Dorothee Nashan; Rainer Rompel; Sebastian Rotterdam; Uwe Trefzer; Selma Ugurel; Christine Windemuth-Kieselbach; Thomas K Eigentler; Dirk Schadendorf
A first prospective population-based analysis investigating the actual practice of melanoma diagnosis, treatment and follow-up.
European journal of cancer (Oxford, England : 1990) 2011;47(13):1977-89.
2011: Ruixia Liang; Dirk Schadendorf; Andrea R Wallace; Brian P Rubin
The phosphatidyl inositol 3-kinase pathway is central to the pathogenesis of Kit-activated melanoma.
Pigment cell & melanoma research 2011;24(4):714-23.
2011: Joachim Klode; A Körber; Dirk Schadendorf; L Schöttler; I Stoffels; Joachim Dissemond
Investigation of adhesion of modern wound dressings: a comparative analysis of 56 different wound dressings.
Journal of the European Academy of Dermatology and Venereology : JEADV 2011;25(8):933-9.
2011: Poulam M Patel; Cornelis J A Punt; Caroline Robert; Dirk Schadendorf; Alain Spatz; Stefan Suciu; John A Thompson; Uwe Trefzer; Sanjiv S Agarwala; Juergen Becker; Robert Conry; Neville Davidson; Reinhard Dummer; Alexander M M Eggermont; Kristel Engelen; Wen-Jen Hwu; Ulrich Keilholz; Wim H Kruit; Laurent Mortier
Extended schedule, escalated dose temozolomide versus dacarbazine in stage IV melanoma: final results of a randomised phase III study (EORTC 18032).
European journal of cancer (Oxford, England : 1990) 2011;47(10):1476-83.
2011: Friederike Egberts; L Frey; Claus Garbe; R Gutzmer; J C Hassel; J C Becker; Carola Berking; A Degen; K C Kaehler; E Livingstone; C Mauch; Peter Mohr; Ted King; Dirk Schadendorf; F Schenck; U Trefzer; Selma Ugurel; Michael Weichenthal; T Wilhelm; Axel Hauschild
Sorafenib and pegylated interferon-α2b in advanced metastatic melanoma: a multicenter phase II DeCOG trial.
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 2011;22(7):1667-74.
2011: Paul B Chapman; Brigitte Dreno; Reinhard Dummer; Alexander M M Eggermont; Keith T Flaherty; Claus Garbe; John B Haanen; Axel Hauschild; David Hogg; Jeannie Hou; Thomas Jouary; John M Kirkwood; James Larkin; Celeste Lebbe; Richard J Lee; Jiang Li; Paul Lorigan; Michele Maio; Betty Nelson; Keith Nolop; Steven J O'Day; Antoni Ribas; Caroline Robert; Dirk Schadendorf; Jeffrey A Sosman; Alessandro Testori; Grant A McArthur; Paolo Ascierto
Improved survival with vemurafenib in melanoma with BRAF V600E mutation.
The New England journal of medicine 2011;364(26):2507-16.
2011: Sabine Vits; Elvir Cesko; Paul Enck; Uwe Hillen; Dirk Schadendorf; Manfred Schedlowski
Behavioural conditioning as the mediator of placebo responses in the immune system.
Philosophical transactions of the Royal Society of London. Series B, Biological sciences 2011;366(1572):1799-807.
2011: David Schrama; Dominique Scherer; Michael Schneider; Marc Zapatka; Eva-Bettina Bröcker; Dirk Schadendorf; Selma Ugurel; Rajiv Kumar; Jürgen C Becker
ERCC5 p.Asp1104His and ERCC2 p.Lys751Gln polymorphisms are independent prognostic factors for the clinical course of melanoma.
The Journal of investigative dermatology 2011;131(6):1280-90.
2011: Stanley P L Leong; jeffrey gershenwald; Seng-Jaw Soong; Dirk Schadendorf; Ahmad A Tarhini; Sanjiv Agarwala; Axel Hauschild; Christopher W M Soon; Adil Daud; Mohammed Kashani-Sabet
Cutaneous melanoma: a model to study cancer metastasis.
Journal of surgical oncology 2011;103(6):538-49.
2011: Thomas K Eigentler; Adina Figl; Dietmar Krex; Peter Mohr; Cornelia Mauch; Knut Rass; Azize Bostroem; Oliver Heese; Oliver Koelbl; Claus Garbe; Dirk Schadendorf
Number of metastases, serum lactate dehydrogenase level, and type of treatment are prognostic factors in patients with brain metastases of malignant melanoma.
Cancer 2011;117(8):1697-703.
2011: L Huptas; N Rompoti; S Herbig; Andreas Körber; J Klode; Dirk Schadendorf; Joachim Dissemond
[A new topically applied morphine gel for the pain treatment in patients with chronic leg ulcers: first results of a clinical investigation].
Der Hautarzt; Zeitschrift für Dermatologie, Venerologie, und verwandte Gebiete 2011;62(4):280-6.
2011: Iris Helfrich; Dirk Schadendorf
Blood vessel maturation, vascular phenotype and angiogenic potential in malignant melanoma: one step forward for overcoming anti-angiogenic drug resistance?
Molecular oncology 2011;5(2):137-49.
2011: Philipp M Amann; Dirk Schadendorf; Robert W Owen; Bernhard Korn; Stefan B Eichmüller; Alexandr V Bazhin
Retinal and retinol are potential regulators of gene expression in the keratinocyte cell line HaCaT.
Experimental dermatology 2011;20(4):373-5.
2011: Thomas Schneider; Silvia Kimpfler; Arne Warth; Philipp A Schnabel; Hendrik Dienemann; Dirk Schadendorf; Hans Hoffmann; Viktor Umansky
Foxp3(+) regulatory T cells and natural killer cells distinctly infiltrate primary tumors and draining lymph nodes in pulmonary adenocarcinoma.
Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer 2011;6(3):432-8.
2011: I Stoffels; Joachim Dissemond; A Körber; Uwe Hillen; T Poeppel; Dirk Schadendorf; Joachim Klode
Reliability and cost-effectiveness of sentinel lymph node excision under local anaesthesia versus general anaesthesia for malignant melanoma: a retrospective analysis in 300 patients with malignant melanoma AJCC Stages I and II.
Journal of the European Academy of Dermatology and Venereology : JEADV 2011;25(3):306-10.
2011: Andreas Körber; Joachim Klode; Sammy Al-Benna; Caroline Wax; Dirk Schadendorf; Lars Steinstraesser; Joachim Dissemond
Etiology of chronic leg ulcers in 31,619 patients in Germany analyzed by an expert survey.
Journal der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : JDDG 2011;9(2):116-21.
2011: Heike Niessner; Daniela Beck; Tobias Sinnberg; Konstantinos G Lasithiotakis; Evelyn Maczey; Jeannette Gogel; Sascha Venturelli; Alexander Berger; Mario Mauthe; Mahmoud Toulany; Keith Flaherty; Martin Schaller; Dirk Schadendorf; Tassula Proikas-Cezanne; Birgit Schittek; Claus Garbe; Dagmar Kulms; Friedegund Meier
The farnesyl transferase inhibitor lonafarnib inhibits mTOR signaling and enforces sorafenib-induced apoptosis in melanoma cells.
The Journal of investigative dermatology 2011;131(2):468-79.
2011: Andreas Gast; Kari Hemminki; Justo Lorenzo Bermejo; Andreas Brandt; Rainer Claus; Christoph Plass; Dirk Schadendorf; Antje Sucker; Alexander Weber; Marianne Weires; Rajiv Kumar
Association of inherited variation in Toll-like receptor genes with malignant melanoma susceptibility and survival.
PloS one 2011;6(9):e24370.
2011: Axel Hauschild; Oliver Kölbl; Andreas Mackensen; Dirk Schadendorf
[Forward].
Onkologie 2011;34 Suppl 2():1.
2011: Sandra Boehncke; Katja Hardt; Dirk Schadendorf; Reinhard Henschler; Wolf-Henning Boehncke; Beatrice Duthey
Endogenous μ-opioid peptides modulate immune response towards malignant melanoma.
Experimental dermatology 2011;20(1):24-8.
2010: Sigrid M C Broekaert; Ritu Roy; Ichiro Okamoto; Joost van den Oord; Jürgen Bauer; Claus Garbe; Raymond L Barnhill; Klaus J Busam; Alistair J Cochran; Martin G Cook; David E Elder; Stanley W McCarthy; Martin C Mihm; Dirk Schadendorf; Richard A Scolyer; Alan Spatz; Boris C Bastian
Genetic and morphologic features for melanoma classification.
Pigment cell & melanoma research 2010;23(6):763-70.
2010: Dominique Scherer; Sivaramakrishna Rachakonda; Sabrina Angelini; Franziska Mehnert; Antje Sucker; Friederike Egberts; Axel Hauschild; Kari Hemminki; Dirk Schadendorf; Rajiv Kumar
Association between the germline MC1R variants and somatic BRAF/NRAS mutations in melanoma tumors.
The Journal of investigative dermatology 2010;130(12):2844-8.
2010: Maren Weindorf; Andreas Körber; Dirk Schadendorf; Joachim Dissemond
[Klippel-trénaunay syndrome - a rare cause of a chronic leg ulcer].
Medizinische Klinik (Munich, Germany : 1983) 2010;105(11):841-4.
2010: Elisabeth Livingstone; Lisa Zimmer; Sarah Piel; Dirk Schadendorf
PLX4032: does it keep its promise for metastatic melanoma treatment?
Expert opinion on investigational drugs 2010;19(11):1439-49.
2010: Katharina C Kaehler; Sarah Piel; Elisabeth Livingstone; Bastian Schilling; Axel Hauschild; Dirk Schadendorf
Update on immunologic therapy with anti-CTLA-4 antibodies in melanoma: identification of clinical and biological response patterns, immune-related adverse events, and their management.
Seminars in oncology 2010;37(5):485-98.
2010: Adina Figl; Dominique Scherer; Eduardo Nagore; Justo Lorenzo Bermejo; Rafael Botella-Estrada; Andreas Gast; Ranjit K Thirumaran; Dolores Planelles; Kari Hemminki; Dirk Schadendorf; Rajiv Kumar
Single-nucleotide polymorphisms in DNA-repair genes and cutaneous melanoma.
Mutation research 2010;702(1):8-16.
2010: J C Hassel; Antje Sucker; Lutz Edler; H Kurzen; I Moll; C Stresemann; K Spieth; C Mauch; K Rass; Reinhard Dummer; Dirk Schadendorf
MGMT gene promoter methylation correlates with tolerance of temozolomide treatment in melanoma but not with clinical outcome.
British journal of cancer 2010;103(6):820-6.
2010: Ravikumar Muthuswamy; Jan Muller-Berghaus; Uwe Haberkorn; Todd A Reinhart; Dirk Schadendorf; Pawel Kalinski
PGE(2) transiently enhances DC expression of CCR7 but inhibits the ability of DCs to produce CCL19 and attract naive T cells.
Blood 2010;116(9):1454-9.
2010: Richard Bränström; Nadine A Kasparian; Yu-mei Chang; Paul Affleck; Aad Tibben; Lisa G Aspinwall; Esther Azizi; Orna Baron-Epel; Linda Battistuzzi; Wilma Bergman; William Bruno; May Chan; Francisco Cuellar; Tadeusz Debniak; Dace Pjanova; Slawomir Ertmanski; Adina Figl; Melinda Gonzalez; Nicholas K Hayward; Marko Hocevar; Peter A Kanetsky; Sancy A Leachman; Olita Heisele; Jane Palmer; Barbara Peric; Susana Puig; Dirk Schadendorf; Nelleke A Gruis; Julia Newton-Bishop; Yvonne Brandberg
Predictors of sun protection behaviors and severe sunburn in an international online study.
Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology 2010;19(9):2199-210.
2010: A Körber; EN Schmid; J Buer; J Klode; Dirk Schadendorf; Joachim Dissemond
Bacterial colonization of chronic leg ulcers: current results compared with data 5 years ago in a specialized dermatology department.
Journal of the European Academy of Dermatology and Venereology : JEADV 2010;24(9):1017-25.
2010: F Stephen Hodi; Steven J O'Day; David F McDermott; Robert W Weber; Jeffrey A Sosman; John B Haanen; Rene Gonzalez; Caroline Robert; Dirk Schadendorf; Jessica C Hassel; Wallace Akerley; Alfons J M van den Eertwegh; Jose Lutzky; Paul Lorigan; Julia M Vaubel; Gerald P Linette; David Hogg; Christian H Ottensmeier; Celeste Lebbé; Christian Peschel; Ian Quirt; Joseph I Clark; Jedd D Wolchok; Jeffrey S Weber; Jason Tian; Michael J Yellin; Geoffrey M Nichol; Axel Hoos; Walter J Urba
Improved survival with ipilimumab in patients with metastatic melanoma.
The New England journal of medicine 2010;363(8):711-23.
2010: Andreas Gast; Dominique Scherer; Bowang Chen; Sandra Bloethner; Stephanie Melchert; Antje Sucker; Kari Hemminki; Dirk Schadendorf; Rajiv Kumar
Somatic alterations in the melanoma genome: a high-resolution array-based comparative genomic hybridization study.
Genes, chromosomes & cancer 2010;49(8):733-45.
2010: J Klode; K Klötgen; A Körber; Dirk Schadendorf; Joachim Dissemond
Polidocanol foam sclerotherapy is a new and effective treatment for post-operative lymphorrhea and lymphocele.
Journal of the European Academy of Dermatology and Venereology : JEADV 2010;24(8):904-9.
2010: yann godet; Juliette Desfrançois; Virginie Vignard; Dirk Schadendorf; Amir Khammari; Brigitte Dreno; Francine Jotereau; Nathalie Labarrière
Frequent occurrence of high affinity T cells against MELOE-1 makes this antigen an attractive target for melanoma immunotherapy.
European journal of immunology 2010;40(6):1786-94.
2010: Adam Dangoor; Paul Lorigan; Ulrich Keilholz; Dirk Schadendorf; Adrian Harris; Christian Ottensmeier; John Smyth; Klaus Hoffmann; Richard Anderson; Martin Cripps; Joerg Schneider; Robert Hawkins
Clinical and immunological responses in metastatic melanoma patients vaccinated with a high-dose poly-epitope vaccine.
Cancer immunology, immunotherapy : CII 2010;59(6):863-73.
2010: A-C Riehemann; Andreas Körber; N Voshege; Dirk Schadendorf; Joachim Dissemond
[Perianal ulcerations caused by potassium permanganate bath].
Der Hautarzt; Zeitschrift für Dermatologie, Venerologie, und verwandte Gebiete 2010;61(5):435-8.
2010: Iris Helfrich; Inka Scheffrahn; Sönke Bartling; Joachim Weis; Verena von Felbert; Mark Middleton; Masahi Kato; Süleyman Ergün; Dirk Schadendorf
Resistance to antiangiogenic therapy is directed by vascular phenotype, vessel stabilization, and maturation in malignant melanoma.
The Journal of experimental medicine 2010;207(3):491-503.
2010: Alexandr V Bazhin; Vojtech Tambor; Boyan Dikov; Pavel P Philippov; Dirk Schadendorf; Stefan B Eichmüller
cGMP-phosphodiesterase 6, transducin and Wnt5a/Frizzled-2-signaling control cGMP and Ca(2+) homeostasis in melanoma cells.
Cellular and molecular life sciences : CMLS 2010;67(5):817-28.
2010: Thomas Jansen; Bodo C Melnik; Dirk Schadendorf
Steroid-induced periorificial dermatitis in children--clinical features and response to azelaic acid.
Pediatric dermatology 2010;27(2):137-42.
2010: Axel Hauschild; Michael Weichenthal; Ted King; Ruthild Linse; Carola Berking; Jörg Böttjer; Thomas Vogt; Konstanze Spieth; Thomas Eigentler; Norbert H Brockmeyer; Annette Stein; Helmut Näher; Dirk Schadendorf; Peter Mohr; Martin Kaatz; Michael Tronnier; Rüdiger Hein; Gerold Schuler; Friederike Egberts; Claus Garbe
Efficacy of low-dose interferon {alpha}2a 18 versus 60 months of treatment in patients with primary melanoma of >= 1.5 mm tumor thickness: results of a randomized phase III DeCOG trial.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2010;28(5):841-6.
2010: Teresa Peccerella; Nadine Lukan; Ralf Hofheinz; Dirk Schadendorf; Markus Kostrezewa; Michael Neumaier; Peter Findeisen
Endoprotease profiling with double-tagged peptide substrates: a new diagnostic approach in oncology.
Clinical chemistry 2010;56(2):272-80.
2010: Jedd D Wolchok; Bart Neyns; Gerald Linette; Sylvie Negrier; Jose Lutzky; Luc Thomas; William Waterfield; Dirk Schadendorf; Michael Smylie; Troy Guthrie; Jean-Jacques Grob; Jason Chesney; Kevin Chin; Kun Chen; Axel Hoos; Steven J O'Day; Celeste Lebbé
Ipilimumab monotherapy in patients with pretreated advanced melanoma: a randomised, double-blind, multicentre, phase 2, dose-ranging study.
The lancet oncology 2010;11(2):155-64.
2010: Marna G Bouwhuis; Andreas Gast; Adina Figl; Alexander M M Eggermont; Kari Hemminki; Dirk Schadendorf; Rajiv Kumar
Polymorphisms in the CD28/CTLA4/ICOS genes: role in malignant melanoma susceptibility and prognosis?
Cancer immunology, immunotherapy : CII 2010;59(2):303-12.
2010: Wolfram Osen; Sabine Soltek; Mingxia Song; Barbara Leuchs; Julia Steitz; Thomas Tüting; Stefan B Eichmüller; Xuan Duc Nguyen; Dirk Schadendorf; Annette Paschen
Screening of human tumor antigens for CD4 T cell epitopes by combination of HLA-transgenic mice, recombinant adenovirus and antigen peptide libraries.
PloS one 2010;5(11):e14137.
2010: Jedd D Wolchok; Jeffrey S Weber; Omid Hamid; Celeste Lebbé; Michele Maio; Dirk Schadendorf; Veerle de Pril; Kevin Heller; Tai-Tsang Chen; Ramy Ibrahim; Axel Hoos; Steven J O'Day
Ipilimumab efficacy and safety in patients with advanced melanoma: a retrospective analysis of HLA subtype from four trials.
Cancer immunity 2010;10():9.
2010: Alexandr V Bazhin; Sarah Kahnert; Silvia Kimpfler; Dirk Schadendorf; Viktor Umansky
Distinct metabolism of cyclic adenosine monophosphate in regulatory and helper CD4+ T cells.
Molecular immunology 2010;47(4):678-84.
2010: Katharina C Kaehler; Vernon K Sondak; Dirk Schadendorf; Axel Hauschild
Pegylated interferons: prospects for the use in the adjuvant and palliative therapy of metastatic melanoma.
European journal of cancer (Oxford, England : 1990) 2010;46(1):41-6.
2010: Uwe Hillen; Sabine Meyer; Dirk Schadendorf; Bernhard Kremens
Photopheresis in pediatric patients with low-body weight using the UVAR XTS system.
Journal der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : JDDG 2010;8(1):32-7.
2009: Mohammed Kashani-Sabet; Suraj S Venna; Mehdi Nosrati; Javier Rangel; Antje Sucker; Friederike Egberts; Frederick L Baehner; Jeff Simko; Stanley P L Leong; Christopher Haqq; Axel Hauschild; Dirk Schadendorf; James R Miller; Richard W Sagebiel
A multimarker prognostic assay for primary cutaneous melanoma.
Clinical cancer research : an official journal of the American Association for Cancer Research 2009;15(22):6987-92.
2009: Silvia Kimpfler; Alexandra Sevko; Sabine Ring; Christine Falk; Wolfram Osen; Kathrin Frank; Masashi Kato; Karsten Mahnke; Dirk Schadendorf; Viktor Umansky
Skin melanoma development in ret transgenic mice despite the depletion of CD25+Foxp3+ regulatory T cells in lymphoid organs.
Journal of immunology (Baltimore, Md. : 1950) 2009;183(10):6330-7.
2009: Dominique Scherer; Eduardo Nagore; Justo Lorenzo Bermejo; Adina Figl; Rafael Botella-Estrada; Ranjit K Thirumaran; Sabrina Angelini; Kari Hemminki; Dirk Schadendorf; Rajiv Kumar
Melanocortin receptor 1 variants and melanoma risk: a study of 2 European populations.
International journal of cancer. Journal international du cancer 2009;125(8):1868-75.
2009: Sanjiv S Agarwala; Jurgen C Becker; Alexander M Eggermont; Keith T Flaherty; Claus Garbe; Alisa M Goldstein; Allan C Halpern; Mohammed Kashani-Sabet; Axel Hauschild; John M Kirkwood; Sancy Leachman; Paul Lorigan; Martin McMahon; Jane Messina; Antoni Ribas; Wolfram E Samlowski; Dirk Schadendorf; Vernon K Sondak
Meeting report: consensus from the first and second Global Workshops in Melanoma November 19-20, 2008.
Pigment cell & melanoma research 2009;22(5):532-43.
2009: Dorota Hoja-Łukowicz; Małgorzata Przybyło; Ewa Pocheć; Anna Drabik; Jerzy Silberring; Marcelina Kremser; Dirk Schadendorf; Piotr Laidler; Anna Lityńska
The new face of nucleolin in human melanoma.
Cancer immunology, immunotherapy : CII 2009;58(9):1471-80.
2009: Annette Paschen; Antje Sucker; Bettina Hill; Iris Moll; Marc Zapatka; Xuan Duc Nguyen; Geok Choo Sim; Isabelle Gutmann; Jessica Hassel; Jürgen C Becker; Alexander Steinle; Dirk Schadendorf; Selma Ugurel
Differential clinical significance of individual NKG2D ligands in melanoma: soluble ULBP2 as an indicator of poor prognosis superior to S100B.
Clinical cancer research : an official journal of the American Association for Cancer Research 2009;15(16):5208-15.
2009: Dirk Schadendorf; S M Algarra; L Bastholt; G Cinat; Brigitte Dreno; A M M Eggermont; E Espinosa; J Guo; Axel Hauschild; T Petrella; J Schachter; P Hersey
Immunotherapy of distant metastatic disease.
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 2009;20 Suppl 6():vi41-50.
2009: Axel Hauschild; Michael Weichenthal; Ted King; Ruthild Linse; Jens Ulrich; Rudolf Stadler; Matthias Volkenandt; Stephan Grabbe; Ulrike Proske; Dirk Schadendorf; Norbert Brockmeyer; Thomas Vogt; Rainer Rompel; Roland Kaufmann; Martin Kaatz; Helmut Näher; Peter Mohr; Thomas Eigentler; Elisabeth Livingstone; Claus Garbe
Prospective randomized multicenter adjuvant dermatologic cooperative oncology group trial of low-dose interferon alfa-2b with or without a modified high-dose interferon alfa-2b induction phase in patients with lymph node-negative melanoma.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2009;27(21):3496-502.
2009: Fang Zhao; Christine Falk; Wolfram Osen; Masashi Kato; Dirk Schadendorf; Viktor Umansky
Activation of p38 mitogen-activated protein kinase drives dendritic cells to become tolerogenic in ret transgenic mice spontaneously developing melanoma.
Clinical cancer research : an official journal of the American Association for Cancer Research 2009;15(13):4382-90.
2009: andrew bottomley; Corneel Coens; Stefan Suciu; mario santinami; Willem Kruit; Alessandro Testori; Jeremy Marsden; Cornelis Punt; François Salès; Martin Gore; Rona Mackie; Zvonko Kusic; Reinhard Dummer; Poulam Patel; Dirk Schadendorf; Alain Spatz; Ulrich Keilholz; Alexander Eggermont
Adjuvant therapy with pegylated interferon alfa-2b versus observation in resected stage III melanoma: a phase III randomized controlled trial of health-related quality of life and symptoms by the European Organisation for Research and Treatment of Cancer Melanoma Group.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2009;27(18):2916-23.
2009: Axel Hauschild; Sanjiv S Agarwala; Uwe Trefzer; David Hogg; Caroline Robert; Peter Hersey; Alexander Eggermont; Stephan Grabbe; Rene Gonzalez; Jens Gille; Christian Peschel; Dirk Schadendorf; Claus Garbe; Steven O'Day; Adil Daud; J Michael White; Chenghua Xia; Kiran Patel; John M Kirkwood; Ulrich Keilholz
Results of a phase III, randomized, placebo-controlled study of sorafenib in combination with carboplatin and paclitaxel as second-line treatment in patients with unresectable stage III or stage IV melanoma.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2009;27(17):2823-30.
2009: Alexander M M Eggermont; Dirk Schadendorf
Melanoma and immunotherapy.
Hematology/oncology clinics of North America 2009;23(3):547-64, ix-x.
2009: Andreas Körber; Dirk Schadendorf; Joachim Dissemond
[Causes of leg ulcers. Analysis of the data from a dermatologic wound care center].
Der Hautarzt; Zeitschrift für Dermatologie, Venerologie, und verwandte Gebiete 2009;60(6):483-8.
2009: Andreas Lange; Claudia Kistler; Tanja B Jutzi; Alexandr V Bazhin; Claus-Detlev Klemke; Dirk Schadendorf; Stefan B Eichmüller
Detergent fractionation with subsequent subtractive suppression hybridization as a tool for identifying genes coding for plasma membrane proteins.
Experimental dermatology 2009;18(6):527-35.
2009: Dirk Schadendorf
Peroxisome proliferator-activating receptors: a new way to treat melanoma?
The Journal of investigative dermatology 2009;129(5):1061-3.
2009: Tadepally Lakshmikanth; Shannon Burke; Talib Hassan Ali; Silvia Kimpfler; Francesco Ursini; Loredana Ruggeri; Marusca Capanni; Viktor Umansky; Annette Paschen; Antje Sucker; Daniela Pende; Veronika Groh; Roberto Biassoni; Petter Höglund; Masashi Kato; Kazuko Shibuya; Dirk Schadendorf; Andrea Anichini; Soldano Ferrone; Andrea Velardi; Klas Kärre; Akira Shibuya; Ennio Carbone; Francesco Colucci
NCRs and DNAM-1 mediate NK cell recognition and lysis of human and mouse melanoma cell lines in vitro and in vivo.
The Journal of clinical investigation 2009;119(5):1251-63.
2009: Peter Findeisen; Marc Zapatka; Teresa Peccerella; Heike Matzk; Michael Neumaier; Dirk Schadendorf; Selma Ugurel
Serum amyloid A as a prognostic marker in melanoma identified by proteomic profiling.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2009;27(13):2199-208.
2009: Sarah Piel; Natalia Denisjuk; Dirk Schadendorf; Joachim Dissemond
Giant pilomatricoma: a benign tumor in an uncommon presentation.
The Journal of pediatrics 2009;154(4):623.
2009: Nicole Schwinn; Daria Vokhminova; Antje Sucker; Sonja Textor; Sandra Striegel; Iris Moll; Norman Nausch; Jochen Tuettenberg; Alexander Steinle; Adelheid Cerwenka; Dirk Schadendorf; Annette Paschen
Interferon-gamma down-regulates NKG2D ligand expression and impairs the NKG2D-mediated cytolysis of MHC class I-deficient melanoma by natural killer cells.
International journal of cancer. Journal international du cancer 2009;124(7):1594-604.
2009: Iris Helfrich; Lutz Edler; Antje Sucker; Markus Thomas; Sven Christian; Dirk Schadendorf; Hellmut G Augustin
Angiopoietin-2 levels are associated with disease progression in metastatic malignant melanoma.
Clinical cancer research : an official journal of the American Association for Cancer Research 2009;15(4):1384-92.
2009: Patrick Nasarre; Markus Thomas; Karoline Kruse; Iris Helfrich; Vivien Wolter; Carleen Deppermann; Dirk Schadendorf; Gavin Thurston; Ulrike Fiedler; Hellmut G Augustin
Host-derived angiopoietin-2 affects early stages of tumor development and vessel maturation but is dispensable for later stages of tumor growth.
Cancer research 2009;69(4):1324-33.
2009: Adina Figl; Dominique Scherer; Eduardo Nagore; Justo Lorenzo Bermejo; Elke Dickes; Ranjit K Thirumaran; Andreas Gast; Kari Hemminki; Rajiv Kumar; Dirk Schadendorf
Single nucleotide polymorphisms in DNA repair genes XRCC1 and APEX1 in progression and survival of primary cutaneous melanoma patients.
Mutation research 2009;661(1-2):78-84.
2009: yann godet; Annabelle Bonnin; Yannik Guilloux; Virginie Vignard; Dirk Schadendorf; Brigitte Dreno; Francine Jotereau; Nathalie Labarriere
A new tyrosinase epitope recognized in the HLA-B*4002 context by CTL from melanoma patients.
Cancer immunology, immunotherapy : CII 2009;58(2):271-80.
2009: Alexandr V Bazhin; Claudia Dalke; Nadine Willner; Oliver Abschütz; Hannes G H Wildberger; Pavel P Philippov; Reinhard Dummer; Jochen Graw; Martin Hrabé De Angelis; Dirk Schadendorf; Viktor Umansky; Stefan B Eichmüller
Cancer-retina antigens as potential paraneoplastic antigens in melanoma-associated retinopathy.
International journal of cancer. Journal international du cancer 2009;124(1):140-9.
2008: Jan Muller-Berghaus; Markus J Kemper; Bernd Hoppe; Uwe Querfeld; Dirk E Müller-Wiefel; Grant Morahan; Dirk Schadendorf; Klaus Tenbrock
The clinical course of steroid-sensitive childhood nephrotic syndrome is associated with a functional IL12B promoter polymorphism.
Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association 2008;23(12):3841-4.
2008: Viktor Umansky; Oliver Abschuetz; Wolfram Osen; Marcel Ramacher; Fang Zhao; Masashi Kato; Dirk Schadendorf
Melanoma-specific memory T cells are functionally active in Ret transgenic mice without macroscopic tumors.
Cancer research 2008;68(22):9451-8.
2008: Thomas K Eigentler; Peter Radny; Axel Hauschild; Ralf Gutzmer; Ruthild Linse; Claudia Pföhler; Stephan N Wagner; Dirk Schadendorf; Ulf Ellwanger; Claus Garbe
Adjuvant treatment with vindesine in comparison to observation alone in patients with metastasized melanoma after complete metastasectomy: a randomized multicenter trial of the German Dermatologic Cooperative Oncology Group.
Melanoma research 2008;18(5):353-8.
2008: Axel Hauschild; Reinhard Dummer; Selma Ugurel; Katharina C Kaehler; Friederike Egberts; Wolfram Fink; Jeannine Both-Skalsky; Barbara Laetsch; Dirk Schadendorf
Combined treatment with pegylated interferon-alpha-2a and dacarbazine in patients with advanced metastatic melanoma: a phase 2 study.
Cancer 2008;113(6):1404-11.
2008: Axel Hauschild; Uwe Trefzer; Claus Garbe; Katharina C Kaehler; Selma Ugurel; Felix Kiecker; Thomas Eigentler; Heiko Krissel; Astrid Schott; Dirk Schadendorf
Multicenter phase II trial of the histone deacetylase inhibitor pyridylmethyl-N-{4-[(2-aminophenyl)-carbamoyl]-benzyl}-carbamate in pretreated metastatic melanoma.
Melanoma research 2008;18(4):274-8.
2008: Yuansheng Sun; Mingxia Song; Elke Jäger; Christina Schwer; Stefan Stevanovic; Sven Flindt; Julia Karbach; Xuan D Nguyen; Dirk Schadendorf; Klaus Cichutek
Human CD4+ T lymphocytes recognize a vascular endothelial growth factor receptor-2-derived epitope in association with HLA-DR.
Clinical cancer research : an official journal of the American Association for Cancer Research 2008;14(13):4306-15.
2008: Zane Kalniņa; Karīna Siliņa; Irēna Meistere; Pawel Zayakin; Alexander Rivosh; Artūrs Abols; Mārcis Leja; Olga Minenkova; Dirk Schadendorf; Aija Linē
Evaluation of T7 and lambda phage display systems for survey of autoantibody profiles in cancer patients.
Journal of immunological methods 2008;334(1-2):37-50.
2008: Claus Garbe; Dirk Schadendorf; Wilhelm Stolz; Matthias Volkenandt; Uwe Reinhold; Rolf-Dieter Kortmann; Christoph Kettelhack; Bernhard Frerich; Ulrich Keilholz; Reinhard Dummer; Günther Sebastian; Wolfgang Tilgen; Gerold Schuler; Andreas Mackensen; Roland Kaufmann; Axel Hauschild
Short German guidelines: malignant melanoma.
Journal der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : JDDG 2008;6 Suppl 1():S9-S14.
2008: Reinhard Dummer; Dirk Schadendorf
How melanoma is treated in real life.
Archives of dermatology 2008;144(5):664-5.
2008: Silvia Hahn; Selma Ugurel; Kay-Martin Hanschmann; Heike Strobel; Christiane Tondera; Dirk Schadendorf; Johannes Löwer; Roswitha Löwer
Serological response to human endogenous retrovirus K in melanoma patients correlates with survival probability.
AIDS research and human retroviruses 2008;24(5):717-23.
2008: Selma Ugurel; David Schrama; Gunhild Keller; Dirk Schadendorf; Eva-Bettina Bröcker; Roland Houben; Marc Zapatka; Wolfram Fink; Howard Kaufman; Jürgen C Becker
Impact of the CCR5 gene polymorphism on the survival of metastatic melanoma patients receiving immunotherapy.
Cancer immunology, immunotherapy : CII 2008;57(5):685-91.
2008: Claus Garbe; Axel Hauschild; Matthias Volkenandt; Dirk Schadendorf; Wilhelm Stolz; Uwe Reinhold; Rolf-Dieter Kortmann; Christoph Kettelhack; Bernhard Frerich; Ulrich Keilholz; Reinhard Dummer; Günther Sebastian; Wolfgang Tilgen; Gerold Schuler; Andreas Mackensen; Roland Kaufmann
Evidence-based and interdisciplinary consensus-based German guidelines: systemic medical treatment of melanoma in the adjuvant and palliative setting.
Melanoma research 2008;18(2):152-60.
2008: Konstanze Spieth; Roland Kaufmann; R Dummer; Claus Garbe; J C Becker; A Hauschild; Wolfgang Tilgen; S Ugurel; M Beyeler; E B Bröcker; K C Kaehler; C Pföhler; Jens Gille; U Leiter; Dirk Schadendorf
Temozolomide plus pegylated interferon alfa-2b as first-line treatment for stage IV melanoma: a multicenter phase II trial of the Dermatologic Cooperative Oncology Group (DeCOG).
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 2008;19(4):801-6.
2008: Tanja B Hartmann; Eva Mattern; Nicole Wiedemann; Remco van Doorn; Rein Willemze; Takako Niikura; Ralf Hildenbrand; Dirk Schadendorf; Stefan B Eichmüller
Identification of selectively expressed genes and antigens in CTCL.
Experimental dermatology 2008;17(4):324-34.
2008: Reinhard Dummer; Axel Hauschild; Juergen C Becker; Jean-Jacques Grob; Dirk Schadendorf; Veronica Tebbs; Jeannine Skalsky; Katharina C Kaehler; Stephanie Moosbauer; Ruth Clark; Tze-Chiang Meng; Mirjana Urosevic-Maiwald
An exploratory study of systemic administration of the toll-like receptor-7 agonist 852A in patients with refractory metastatic melanoma.
Clinical cancer research : an official journal of the American Association for Cancer Research 2008;14(3):856-64.
2008: Claus Garbe; Axel Hauschild; Matthias Volkenandt; Dirk Schadendorf; Wilhelm Stolz; Uwe Reinhold; Rolf-Dieter Kortmann; Christoph Kettelhack; Bernhard Frerich; Ulrich Keilholz; Reinhard Dummer; Günther Sebastian; Wolfgang Tilgen; Gerold Schuler; Andreas Mackensen; Roland Kaufmann
Evidence and interdisciplinary consensus-based German guidelines: surgical treatment and radiotherapy of melanoma.
Melanoma research 2008;18(1):61-7.
2008: Sven Christian; Renate Winkler; Iris Helfrich; Anja M Boos; Eva Besemfelder; Dirk Schadendorf; Hellmut G Augustin
Endosialin (Tem1) is a marker of tumor-associated myofibroblasts and tumor vessel-associated mural cells.
The American journal of pathology 2008;172(2):486-94.
2008: Xuan Duc Nguyen; Jan Muller-Berghaus; T Kälsch; Dirk Schadendorf; Martin Borggrefe; Harald Klüter
Differentiation of monocyte-derived dendritic cells under the influence of platelets.
Cytotherapy 2008;10(7):720-9.
2008: Alexandr V Bazhin; Dirk Schadendorf; Robert W Owen; Evgeni Yu Zernii; Pavel P Philippov; Stefan B Eichmüller
Visible light modulates the expression of cancer-retina antigens.
Molecular cancer research : MCR 2008;6(1):110-8.
2007: Claus Garbe; Axel Hauschild; Matthias Volkenandt; Dirk Schadendorf; Wilhelm Stolz; Uwe Reinhold; Rolf-Dieter Kortmann; Christoph Kettelhack; Bernhard Frerich; Ulrich Keilholz; Reinhard Dummer; Günther Sebastian; Wolfgang Tilgen; Gerold Schuler; Andreas Mackensen; Roland Kaufmann
Evidence and interdisciplinary consense-based German guidelines: diagnosis and surveillance of melanoma.
Melanoma research 2007;17(6):393-9.
2007: Selma Ugurel; Roland Houben; David Schrama; Heike Voigt; Marc Zapatka; Dirk Schadendorf; Eva-B Bröcker; Jürgen C Becker
Microphthalmia-associated transcription factor gene amplification in metastatic melanoma is a prognostic marker for patient survival, but not a predictive marker for chemosensitivity and chemotherapy response.
Clinical cancer research : an official journal of the American Association for Cancer Research 2007;13(21):6344-50.
2007: Alexandr V Bazhin; Nicole Wiedemann; Martina Schnölzer; Dirk Schadendorf; Stefan B Eichmüller
Expression of GAGE family proteins in malignant melanoma.
Cancer letters 2007;251(2):258-67.
2007: Balwir Matharoo-Ball; Lucy Ratcliffe; Lee Lancashire; Selma Ugurel; Amanda K Miles; Daniel J Weston; Robert Rees; Dirk Schadendorf; Graham Ball; Colin S Creaser
Diagnostic biomarkers differentiating metastatic melanoma patients from healthy controls identified by an integrated MALDI-TOF mass spectrometry/bioinformatic approach.
Proteomics. Clinical applications 2007;1(6):605-20.
2007: Jochen Utikal; Selma Ugurel; Hjalmar Kurzen; Philipp Erben; Andreas Reiter; Andreas Hochhaus; Thomas Nebe; Ralf Hildenbrand; Uwe Haberkorn; Sergij Goerdt; Dirk Schadendorf
Imatinib as a treatment option for systemic non-Langerhans cell histiocytoses.
Archives of dermatology 2007;143(6):736-40.
2007: Mieun Lee; Claudia Kistler; Tanja B Hartmann; Fang Li; Reinhard Dummer; Edgar Dippel; Nina Booken; Claus-Detlev Klemke; Dirk Schadendorf; Stefan B Eichmüller
Immunoscreening of a cutaneous T-cell lymphoma library for plasma membrane proteins.
Cancer immunology, immunotherapy : CII 2007;56(6):783-95.
2007: Oliver Inhoff; Kristina Doerries; Ruediger Doerries; Johann Scharf; Christoph Groden; Sergij Goerdt; Dirk Schadendorf
Disseminated cutaneous Kaposi sarcoma and progressive multifocal leukoencephalopathy in a patient with idiopathic CD4+ T lymphocytopenia.
Archives of dermatology 2007;143(5):673-5.
2007: Adina Figl; Ranjit K Thirumaran; Selma Ugurel; Andreas Gast; Kari Hemminki; Rajiv Kumar; Dirk Schadendorf
Multiple melanomas after treatment for Hodgkin lymphoma in a non-Dutch p16-Leiden mutation carrier with 2 MC1R high-risk variants.
Archives of dermatology 2007;143(4):495-9.
2007: Alexandr V Bazhin; Dirk Schadendorf; Nadine Willner; Charles De Smet; Anita Heinzelmann; Natalya K Tikhomirova; Viktor Umansky; Pavel P Philippov; Stefan B Eichmüller
Photoreceptor proteins as cancer-retina antigens.
International journal of cancer. Journal international du cancer 2007;120(6):1268-76.
2007: Jürgen C Becker; Eva-B Bröcker; Dirk Schadendorf; Selma Ugurel
Imatinib in melanoma: a selective treatment option based on KIT mutation status?
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2007;25(7):e9.
2007: Jochen Utikal; Dirk Schadendorf; Selma Ugurel
Serologic and immunohistochemical prognostic biomarkers of cutaneous malignancies.
Archives of dermatological research 2007;298(10):469-77.
2007: Teresa Rodríguez; Rosa Méndez; Ana Del Campo; Natalia Aptsiauri; J Martín; G Orozco; Graham Pawelec; Dirk Schadendorf; Francisco Ruiz-Cabello; Federico Garrido
Patterns of constitutive and IFN-gamma inducible expression of HLA class II molecules in human melanoma cell lines.
Immunogenetics 2007;59(2):123-33.
2007: Axel Hauschild; Dirk Schadendorf; Claus Garbe; Selma Ugurel; Katharina C Kähler
New promises in the adjuvant, and palliative treatment of melanoma.
Cancer treatment and research 2007;135():277-92.
2007: Selma Ugurel; Ranjit K Thirumaran; Sandra Bloethner; Andreas Gast; Antje Sucker; Jan Muller-Berghaus; Werner Rittgen; Kari Hemminki; Jürgen C Becker; Rajiv Kumar; Dirk Schadendorf
B-RAF and N-RAS mutations are preserved during short time in vitro propagation and differentially impact prognosis.
PloS one 2007;2(2):e236.
2007: Rosa Méndez; Francisco Ruiz-Cabello; Teresa Rodríguez; Ana Del Campo; Annette Paschen; Dirk Schadendorf; Federico Garrido
Identification of different tumor escape mechanisms in several metastases from a melanoma patient undergoing immunotherapy.
Cancer immunology, immunotherapy : CII 2007;56(1):88-94.
2007: Alexandr V Bazhin; Dirk Schadendorf; Pavel P Philippov; Stefan B Eichmüller
Recoverin as a cancer-retina antigen.
Cancer immunology, immunotherapy : CII 2007;56(1):110-6.
2006: Christine K Kissel; Dirk Schadendorf; Heike Röckmann
The altered apoptotic pathways in cisplatin and etoposide-resistant melanoma cells are drug specific.
Melanoma research 2006;16(6):527-35.
2006: Jinyang Zeng; Jan Muller-Berghaus; Xuan Duc Nguyen; Harald Klüter; Hiltrud Schönhaber; Mingxia Song; Nicole Schwinn; Dirk Schadendorf; Sergij Goerdt; Stefan B Eichmüller; Edgar Dippel
Identification of HLA class I dependent immunogenic peptides from clonotypic TCRbeta expressed in cutaneous T-cell lymphoma.
International journal of cancer. Journal international du cancer 2006;119(10):2476-80.
2006: Jochen Utikal; Adina Thoelke; Jürgen C Becker; Robert Figl; Sergij Goerdt; Dirk Schadendorf; Selma Ugurel
Local cutaneous argyria mimicking melanoma metastases in a patient with disseminated melanoma.
Journal of the American Academy of Dermatology 2006;55(5 Suppl):S92-4.
2006: Dirk Schadendorf; Axel Hauschild; Selma Ugurel; Adina Thoelke; Friederike Egberts; M Kreissig; Ruthild Linse; U Trefzer; T Vogt; Wolfgang Tilgen; P Mohr; Claus Garbe
Dose-intensified bi-weekly temozolomide in patients with asymptomatic brain metastases from malignant melanoma: a phase II DeCOG/ADO study.
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 2006;17(10):1592-7.
2006: Selma Ugurel; Dirk Schadendorf; Claudia Pföhler; Karsten Neuber; Adina Thoelke; Jens Ulrich; Axel Hauschild; Konstanze Spieth; Martin Kaatz; Werner Rittgen; Stefan Delorme; Wolfgang Tilgen; Uwe Reinhold
In vitro drug sensitivity predicts response and survival after individualized sensitivity-directed chemotherapy in metastatic melanoma: a multicenter phase II trial of the Dermatologic Cooperative Oncology Group.
Clinical cancer research : an official journal of the American Association for Cancer Research 2006;12(18):5454-63.
2006: Ranjit K Thirumaran; Adina Thoelke; Selma Ugurel; Kari Hemminki; Dirk Schadendorf; Rajiv Kumar
Re: Association between endothelin receptor B nonsynonymous variants and melanoma risk.
Journal of the National Cancer Institute 2006;98(17):1252-3; author reply 1253.
2006: Izabela Młynarczuk-Biały; Heike Roeckmann; Ulrike Kuckelkorn; Boris Schmidt; Sumaira Umbreen; Jakub Gołab; Antje Ludwig; Christina Montag; Lüder Wiebusch; Christian Hagemeier; Dirk Schadendorf; Peter-M Kloetzel; Ulrike Seifert
Combined effect of proteasome and calpain inhibition on cisplatin-resistant human melanoma cells.
Cancer research 2006;66(15):7598-605.
2006: Jochen Utikal; Anette Zimpfer; Adina Thoelke; Robert Figl; Ralf Hildenbrand; C Kettelhack; Sergij Goerdt; Dirk Schadendorf; Selma Ugurel
Complete remission of multiple satellite and in-transit melanoma metastases after sequential treatment with isolated limb perfusion and topical imiquimod.
The British journal of dermatology 2006;155(2):488-91.
2006: Sandra Bloethner; Kari Hemminki; Ranjit K Thirumaran; Bowang Chen; Jan Muller-Berghaus; Selma Ugurel; Dirk Schadendorf; Rajiv Kumar
Differences in global gene expression in melanoma cell lines with and without homozygous deletion of the CDKN2A locus genes.
Melanoma research 2006;16(4):297-307.
2006: Keith Hoek; Natalie Schlegel; Patricia Brafford; Antje Sucker; Selma Ugurel; Rajiv Kumar; Barbara L Weber; Katherine L Nathanson; David J Phillips; Meenhard Herlyn; Dirk Schadendorf; Reinhard Dummer
Metastatic potential of melanomas defined by specific gene expression profiles with no BRAF signature.
Pigment cell research / sponsored by the European Society for Pigment Cell Research and the International Pigment Cell Society 2006;19(4):290-302.
2006: Adina Thoelke; Hans-Peter Schmid; Robert Figl; Dirk Schadendorf; Selma Ugurel
Jo-1 positive paraneoplastic systemic sclerosis in a patient with metastatic melanoma.
European journal of dermatology : EJD 2006;16(4):428-30.
2006: Annette Paschen; Mingxia Song; Simone Schenk; Jozef Janda; Xuan Duc Nguyen; Wolfram Osen; Dirk Schadendorf; Gernot Geginat
Identification of a cross-reactive HLA-DRB1*0301-restricted CD4 T cell response directed against cholesterol-binding cytolysins from two different pathogens.
Microbes and infection / Institut Pasteur 2006;8(8):2034-43.
2006: Jan Muller-Berghaus; Katrin Ehlert; Selma Ugurel; Viktor Umansky; Mariana Bucur; Volker Schirrmacher; Philipp Beckhove; Dirk Schadendorf
Melanoma-reactive T cells in the bone marrow of melanoma patients: association with disease stage and disease duration.
Cancer research 2006;66(12):5997-6001.
2006: Annette Paschen; Norbert Arens; Antje Sucker; Karin M Greulich-Bode; Ester Fonsatti; Annunziata Gloghini; Sandra Striegel; Nicole Schwinn; Antonino Carbone; Ralf Hildenbrand; Adelheid Cerwenka; Michele Maio; Dirk Schadendorf
The coincidence of chromosome 15 aberrations and beta2-microglobulin gene mutations is causative for the total loss of human leukocyte antigen class I expression in melanoma.
Clinical cancer research : an official journal of the American Association for Cancer Research 2006;12(11 Pt 1):3297-305.
2006: Heike Röckmann; Gabriele Feller; Dirk Schadendorf; Sergij Goerdt
Subacute cutaneous lupus erythematosus on the lines of Blaschko.
European journal of dermatology : EJD 2006;16(3):302-6.
2006: Claus Garbe; Axel Hauschild; Matthias Volkenandt; Dirk Schadendorf; Wilhelm Stolz; Rolf-Dieter Kortmann; Christoph Kettelhack; Bernhard Frerich; Ulrich Keilholz; Reinhard Dummer; Günther Sebastian; Wolfgang Tilgen; Gerold Schuler; Andreas Mackensen; Roland Kaufmann
[Brief guidelines: malignant melanoma of the skin].
Journal der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : JDDG 2006;4(4):344-9.
2006: Balázs Györffy; Violeta Serra; Verena Materna; Reinhold Schäfer; Manfred Dietel; Dirk Schadendorf; Hermann Lage
Analysis of gene expression profiles in melanoma cells with acquired resistance against antineoplastic drugs.
Melanoma research 2006;16(2):147-55.
2006: Dirk Schadendorf; Selma Ugurel; Beatrice Schuler-Thurner; F O Nestle; A Enk; Eva-B Bröcker; S Grabbe; Werner Rittgen; Lutz Edler; Antje Sucker; Christine Zimpfer-Rechner; T Berger; Jivko Kamarashev; G Burg; H Jonuleit; A Tüttenberg; Jürgen C Becker; Petra Keikavoussi; E Kämpgen; Gerold Schuler
Dacarbazine (DTIC) versus vaccination with autologous peptide-pulsed dendritic cells (DC) in first-line treatment of patients with metastatic melanoma: a randomized phase III trial of the DC study group of the DeCOG.
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 2006;17(4):563-70.
2006: Yuansheng Sun; Stefan Stevanovic; Mingxia Song; Astrid Schwantes; C James Kirkpatrick; Dirk Schadendorf; Klaus Cichutek
The kinase insert domain-containing receptor is an angiogenesis-associated antigen recognized by human cytotoxic T lymphocytes.
Blood 2006;107(4):1476-83.
2005: Roland Kaufmann; Konstanze Spieth; Ulrike Leiter; Cornelia Mauch; Peter von den Driesch; Thomas Vogt; Ruthild Linse; Wolfgang Tilgen; Dirk Schadendorf; Jürgen C Becker; Günther Sebastian; Sven Krengel; Lutz Kretschmer; Claus Garbe; Reinhard Dummer
Temozolomide in combination with interferon-alfa versus temozolomide alone in patients with advanced metastatic melanoma: a randomized, phase III, multicenter study from the Dermatologic Cooperative Oncology Group.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2005;23(35):9001-7.
2005: Selma Ugurel; Nellie Bell; Antje Sucker; Anette Zimpfer; Werner Rittgen; Dirk Schadendorf
Tumor type M2 pyruvate kinase (TuM2-PK) as a novel plasma tumor marker in melanoma.
International journal of cancer. Journal international du cancer 2005;117(5):825-30.
2005: Till A Röhn; Annette Reitz; Annette Paschen; Xuan Duc Nguyen; Dirk Schadendorf; Anne B Vogt; Harald Kropshofer
A novel strategy for the discovery of MHC class II-restricted tumor antigens: identification of a melanotransferrin helper T-cell epitope.
Cancer research 2005;65(21):10068-78.
2005: Annette Paschen; Weiqing Jing; Ingo Drexler; Moritz Klemm; Mingxia Song; Jan Muller-Berghaus; Xuan Duc Nguyen; Wolfram Osen; Stefan Stevanovic; Gerd Sutter; Dirk Schadendorf
Melanoma patients respond to a new HLA-A*01-presented antigenic ligand derived from a multi-epitope region of melanoma antigen TRP-2.
International journal of cancer. Journal international du cancer 2005;116(6):944-8.
2005: Till A Röhn; Dirk Schadendorf; Yuansheng Sun; Xuan Duc Nguyen; Daniel Roeder; Hanno Langen; Anne B Vogt; Harald Kropshofer
Melanoma cell necrosis facilitates transfer of specific sets of antigens onto MHC class II molecules of dendritic cells.
European journal of immunology 2005;35(10):2826-39.
2005: Ulrich Keilholz; Cornelis J A Punt; Martin Gore; Wim H J Kruit; Poulam Patel; Danielle Lienard; Jose Thomas; Thomas M Proebstle; Alexander Schmittel; Dirk Schadendorf; Thierry Velu; Sylvie Negrier; Ulrich Kleeberg; Frederic Lehman; Stefan Suciu; Alexander M M Eggermont
Dacarbazine, cisplatin, and interferon-alfa-2b with or without interleukin-2 in metastatic melanoma: a randomized phase III trial (18951) of the European Organisation for Research and Treatment of Cancer Melanoma Group.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2005;23(27):6747-55.
2005: Heike Röckmann; Dirk Schadendorf
Role of apaf-1 in melanoma drug resistance and apoptosis.
The Journal of investigative dermatology 2005;125(2):386-7.
2005: Shahid Mian; Selma Ugurel; Erika Parkinson; Iris Schlenzka; Ian Dryden; Lee Lancashire; Graham Ball; Colin S Creaser; Robert Rees; Dirk Schadendorf
Serum proteomic fingerprinting discriminates between clinical stages and predicts disease progression in melanoma patients.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2005;23(22):5088-93.
2005: Annette Paschen; Mingxia Song; Wolfram Osen; Xuan Duc Nguyen; Jan Muller-Berghaus; Daniela Fink; Nadine Daniel; Mariel Donzeau; Wolfgang Nagel; Harald Kropshofer; Dirk Schadendorf
Detection of spontaneous CD4+ T-cell responses in melanoma patients against a tyrosinase-related protein-2-derived epitope identified in HLA-DRB1*0301 transgenic mice.
Clinical cancer research : an official journal of the American Association for Cancer Research 2005;11(14):5241-7.
2005: Jan Muller-Berghaus; Walter C Olson; Rachel A Moulton; William T Knapp; Dirk Schadendorf; Walter J Storkus
IL-12 production by human monocyte-derived dendritic cells: looking at the single cell.
Journal of immunotherapy (Hagerstown, Md. : 1997) 2005;28(4):306-13.
2005: Sandra Bloethner; Bowang Chen; Kari Hemminki; Jan Muller-Berghaus; Selma Ugurel; Dirk Schadendorf; Rajiv Kumar
Effect of common B-RAF and N-RAS mutations on global gene expression in melanoma cell lines.
Carcinogenesis 2005;26(7):1224-32.
2005: Selma Ugurel; Ralf Hildenbrand; Anette Zimpfer; Paul La Rosée; Peter Paschka; Antje Sucker; Petra Keikavoussi; Jürgen C Becker; Werner Rittgen; Andreas Hochhaus; Dirk Schadendorf
Lack of clinical efficacy of imatinib in metastatic melanoma.
British journal of cancer 2005;92(8):1398-405.
2005: Tanja B Hartmann; Alexandr V Bazhin; Dirk Schadendorf; Stefan B Eichmüller
SEREX identification of new tumor antigens linked to melanoma-associated retinopathy.
International journal of cancer. Journal international du cancer 2005;114(1):88-93.
2005: Ute Bauer; Selma Ugurel; Jochen Utikal; Dirk Schadendorf; Sergij Goerdt
[90-year-old male with a hyperkeratotic lichenoid skin eruption].
Journal der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : JDDG 2005;3(2):137-9.
2004: Wolfram Fink; Christine Zimpfer-Rechner; Adina Thoelke; Robert Figl; M Kaatz; Selma Ugurel; Dirk Schadendorf
Clinical phase II study of pegylated liposomal doxorubicin as second-line treatment in disseminated melanoma.
Onkologie 2004;27(6):540-4.
2004: Selma Ugurel; Monika Lindemann; Dirk Schadendorf; Hans Grosse-Wilde
Altered surface expression patterns of circulating monocytes in cancer patients: impaired capacity of T-cell stimulation?
Cancer immunology, immunotherapy : CII 2004;53(11):1051.
2004: Adina Thoelke; S Willrodt; Axel Hauschild; Dirk Schadendorf
Primary extracutaneous malignant melanoma: a comprehensive review with emphasis on treatment.
Onkologie 2004;27(5):492-9.
2004: Mads Hald Andersen; Joachim Fensterle; Selma Ugurel; Sine Reker Hadrup; Roland Houben; Per Guldberg; Thomas G Berger; Dirk Schadendorf; Uwe Trefzer; Eva-B Bröcker; Ulf R Rapp; Per thor Straten; Jürgen C Becker
Immunogenicity of constitutively active V599EBRaf.
Cancer research 2004;64(15):5456-60.
2004: Jan Muller-Berghaus; K Kern; Annette Paschen; Xuan Duc Nguyen; Harald Klüter; Grant Morahan; Dirk Schadendorf
Deficient IL-12p70 secretion by dendritic cells based on IL12B promoter genotype.
Genes and immunity 2004;5(5):431-4.
2004: Marieke Griffioen; Martina Borghi; Peter I Schrier; Susanne Osanto; Dirk Schadendorf
Analysis of T-cell responses in metastatic melanoma patients vaccinated with dendritic cells pulsed with tumor lysates.
Cancer immunology, immunotherapy : CII 2004;53(8):715-22.
2004: Nicolas Degauque; Dirk Schadendorf; Sophie Brouard; Marina Guillet; Fabien Sébille; Hanni Höhn; Annaïck Pallier; Catherine Ruiz; Alexandre Dupont; Stéphane Chapin; Udo Hofmann; Markus J Maeurer; Jean-Paul Soulillou
Blood T-cell Vbeta transcriptome in melanoma patients.
International journal of cancer. Journal international du cancer 2004;110(5):721-9.
2004: Friederike Fellenberg; Tanja B Hartmann; Reinhard Dummer; Dirk Usener; Dirk Schadendorf; Stefan B Eichmüller
GBP-5 splicing variants: New guanylate-binding proteins with tumor-associated expression and antigenicity.
The Journal of investigative dermatology 2004;122(6):1510-7.
2004: Frank Schoensiegel; Annette Paschen; Stephanie Sieger; Helmut Eskerski; Walter Mier; Heike Rothfels; Jürgen A Kleinschmidt; Dirk Schadendorf; Uwe Haberkorn
MIA (melanoma inhibitory activity) promoter mediated tissue-specific suicide gene therapy of malignant melanoma.
Cancer gene therapy 2004;11(6):408-18.
2004: Selma Ugurel; Dario Uhlig; Claudia Pföhler; Wolfgang Tilgen; Dirk Schadendorf; Uwe Reinhold
Down-regulation of HLA class II and costimulatory CD86/B7-2 on circulating monocytes from melanoma patients.
Cancer immunology, immunotherapy : CII 2004;53(6):551-9.
2004: Axel Gerhardt; Dirk Usener; Michael Keese; Jörg Sturm; Dirk Schadendorf; Stefan B Eichmüller
Tissue expression and sero-reactivity of tumor-specific antigens in colorectal cancer.
Cancer letters 2004;208(2):197-206.
2004: Adina Thölke; Gabriele Feller; Dirk Schadendorf; Sergij Goerdt
[Acute juvenile pityriasis rubra pilaris in a 2-year-old child].
Journal der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : JDDG 2004;2(5):357-9.
2004: Jochen Tüttenberg; Wolfram Fink; Walter Back; Frederik Wenz; Dirk Schadendorf; Claudius Thomé
A rare primary sellar melanoma. Case report.
Journal of neurosurgery 2004;100(5):931-4.
2004: Anne Letsch; Ulrich Keilholz; Dirk Schadendorf; Geraldine Assfalg; Anne Marie Asemissen; Eckhard Thiel; Carmen Scheibenbogen
Functional CCR9 expression is associated with small intestinal metastasis.
The Journal of investigative dermatology 2004;122(3):685-90.
2004: Annette Paschen; Stefan B Eichmüller; Dirk Schadendorf
Identification of tumor antigens and T-cell epitopes, and its clinical application.
Cancer immunology, immunotherapy : CII 2004;53(3):196-203.
2004: Tanja B Hartmann; Daniela Thiel; Reinhard Dummer; Dirk Schadendorf; Stefan B Eichmüller
SEREX identification of new tumour-associated antigens in cutaneous T-cell lymphoma.
The British journal of dermatology 2004;150(2):252-8.
2004: Ulrich Kleeberg; S Suciu; E B Bröcker; Dirk J Ruiter; C Chartier; D Liénard; J Marsden; Dirk Schadendorf; Alexander M M Eggermont
Final results of the EORTC 18871/DKG 80-1 randomised phase III trial. rIFN-alpha2b versus rIFN-gamma versus ISCADOR M versus observation after surgery in melanoma patients with either high-risk primary (thickness >3 mm) or regional lymph node metastasis.
European journal of cancer (Oxford, England : 1990) 2004;40(3):390-402.
2004: Hanno Ehlken; Dirk Schadendorf; Stefan B Eichmüller
Humoral immune response against melanoma antigens induced by vaccination with cytokine gene-modified autologous tumor cells.
International journal of cancer. Journal international du cancer 2004;108(2):307-13.
2003: Heike Rothfels; Annette Paschen; Dirk Schadendorf
Evaluation of combined gene regulatory elements for transcriptional targeting of suicide gene expression to malignant melanoma.
Experimental dermatology 2003;12(6):799-810.
2003: H Röckmann; Dirk Schadendorf
Drug resistance in human melanoma: mechanisms and therapeutic opportunities.
Onkologie 2003;26(6):581-7.
2003: Christine Zimpfer-Rechner; Udo Hofmann; Robert Figl; Jürgen C Becker; Uwe Trefzer; Ivonne Keller; Axel Hauschild; Dirk Schadendorf
Randomized phase II study of weekly paclitaxel versus paclitaxel and carboplatin as second-line therapy in disseminated melanoma: a multicentre trial of the Dermatologic Co-operative Oncology Group (DeCOG).
Melanoma research 2003;13(5):531-6.
2003: Dirk Usener; A Gerhardt; Dirk Schadendorf; Stefan B Eichmüller
Seroreactivity against MAGE-A and LAGE-1 proteins in melanoma patients.
The British journal of dermatology 2003;149(2):282-8.
2003: Axel Hauschild; Michael Weichenthal; Bernd-Rudiger Balda; Jurgen C Becker; Helmut H Wolff; Wolfgang Tilgen; Klaus-Werner Schulte; Johannes Ring; Dirk Schadendorf; Stephan Lischner; Gunter Burg; Reinhard Dummer
Prospective randomized trial of interferon alfa-2b and interleukin-2 as adjuvant treatment for resected intermediate- and high-risk primary melanoma without clinically detectable node metastasis.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2003;21(15):2883-8.
2003: Pranav Sinha; Julia Poland; Sandro Kohl; Martina Schnölzer; Heike Helmbach; Gero Hütter; Hermann Lage; Dirk Schadendorf
Study of the development of chemoresistance in melanoma cell lines using proteome analysis.
Electrophoresis 2003;24(14):2386-404.
2003: Dirk Usener; Dirk Schadendorf; Joachim Koch; Stefan Dübel; Stefan B Eichmüller
cTAGE: a cutaneous T cell lymphoma associated antigen family with tumor-specific splicing.
The Journal of investigative dermatology 2003;121(1):198-206.
2003: Bernd Liedert; Verena Materna; Dirk Schadendorf; Jürgen Thomale; Hermann Lage
Overexpression of cMOAT (MRP2/ABCC2) is associated with decreased formation of platinum-DNA adducts and decreased G2-arrest in melanoma cells resistant to cisplatin.
The Journal of investigative dermatology 2003;121(1):172-6.
2003: Michel Gilliet; Martin Kleinhans; Erica Lantelme; Dirk Schadendorf; Günter Burg; Frank O Nestle
Intranodal injection of semimature monocyte-derived dendritic cells induces T helper type 1 responses to protein neoantigen.
Blood 2003;102(1):36-42.
2003: Selma Ugurel; Dirk Schadendorf
Systemic treatment in advanced melanoma: innovative perspectives.
Onkologie 2003;26(3):234-8.
2003: Klaus K Herfarth; Oxana Izwekowa; Christoph Thilmann; Andrea Pirzkall; Stefan Delorme; Udo Hofmann; Dirk Schadendorf; Dietmar Zierhut; Michael Wannenmacher; Jürgen Debus
Linac-based radiosurgery of cerebral melanoma metastases. Analysis of 122 metastases treated in 64 patients.
Strahlentherapie und Onkologie : Organ der Deutschen Röntgengesellschaft ... [et al] 2003;179(6):366-71.
2003: Selma Ugurel; Ralf Hildenbrand; Edgar Dippel; A Hochhaus; Dirk Schadendorf
Dose-dependent severe cutaneous reactions to imatinib.
British journal of cancer 2003;88(8):1157-9.
2003: Stefan B Eichmüller; Dirk Usener; Daniela Thiel; Dirk Schadendorf
Tumor-specific antigens in cutaneous T-cell lymphoma: expression and sero-reactivity.
International journal of cancer. Journal international du cancer 2003;104(4):482-7.
2003: Dirk Schadendorf; Alexandra Dorn-Beineke; Siegfried Borelli; Gert Riethmuller; Klaus Pantel
Limitations of the immunocytochemical detection of isolated tumor cells in frozen samples of bone marrow obtained from melanoma patients.
Experimental dermatology 2003;12(2):165-71.
2003: Carmen Scheibenbogen; Dirk Schadendorf; Nikolaos E Bechrakis; Dirk Nagorsen; Udo Hofmann; Fotini Servetopoulou; Anne Letsch; Armin Philipp; Michael H Foerster; Alexander Schmittel; Eckhard Thiel; Ulrich Keilholz
Effects of granulocyte-macrophage colony-stimulating factor and foreign helper protein as immunologic adjuvants on the T-cell response to vaccination with tyrosinase peptides.
International journal of cancer. Journal international du cancer 2003;104(2):188-94.
2003: Annette Paschen; Rosa Méndez; Pilar Jimenez; Antje Sucker; Francisco Ruiz-Cabello; Mingxia Song; Federico Garrido; Dirk Schadendorf
Complete loss of HLA class I antigen expression on melanoma cells: a result of successive mutational events.
International journal of cancer. Journal international du cancer 2003;103(6):759-67.
2003: Ruth Oratz; Axel Hauschild; Günther Sebastian; Dirk Schadendorf; Dan Joshua Castro; Eva-B Bröcker; Elaine K Orenberg
Intratumoral cisplatin/adrenaline injectable gel for the treatment of patients with cutaneous and soft tissue metastases of malignant melanoma.
Melanoma research 2003;13(1):59-66.
2003: Heike Helmbach; Pranav Sinha; Dirk Schadendorf
Human melanoma: drug resistance.
Recent results in cancer research. Fortschritte der Krebsforschung. Progrès dans les recherches sur le cancer 2003;161():93-110.
2002: Rainer Wittig; Michelle Nessling; Rainer D Will; Jan Mollenhauer; Rüdiger Salowsky; Ewald Münstermann; Matthias Schick; Heike Helmbach; Brigitte Gschwendt; Bernhard Korn; Petra Kioschis; Peter Lichter; Dirk Schadendorf; Annemarie Poustka
Candidate genes for cross-resistance against DNA-damaging drugs.
Cancer research 2002;62(22):6698-705.
2002: Dirk Schadendorf
Gene-based therapy of malignant melanoma.
Seminars in oncology 2002;29(5):503-12.
2002: Alice J A M Sijts; Yuancheng Sun; Katarina Janek; Sylvie Kral; Annettte Paschen; Dirk Schadendorf; Peter-M Kloetzel
The role of the proteasome activator PA28 in MHC class I antigen processing.
Molecular immunology 2002;39(3-4):165-9.
2002: Stefan B Eichmüller; Dirk Usener; Anita Jochim; Dirk Schadendorf
mRNA expression of tumor-associated antigens in melanoma tissues and cell lines.
Experimental dermatology 2002;11(4):292-301.
2002: U Hofmann; M Szedlak; Werner Rittgen; E G Jung; Dirk Schadendorf
Primary staging and follow-up in melanoma patients--monocenter evaluation of methods, costs and patient survival.
British journal of cancer 2002;87(2):151-7.
2002: Karl Götte; Dirk Usener; Frank Riedel; Karl Hörmann; Dirk Schadendorf; Stefan B Eichmüller
Tumor-associated antigens as possible targets for immune therapy in head and neck cancer: comparative mRNA expression analysis of RAGE and GAGE genes.
Acta oto-laryngologica 2002;122(5):546-52.
2002: Ulrich Keilholz; Peter Martus; Cornelis J A Punt; Wim H J Kruit; G Mooser; Dirk Schadendorf; D Liénard; R Dummer; J Koller; C Voit; Alexander M M Eggermont
Prognostic factors for survival and factors associated with long-term remission in patients with advanced melanoma receiving cytokine-based treatments: second analysis of a randomised EORTC Melanoma Group trial comparing interferon-alpha2a (IFNalpha) and interleukin 2 (IL-2) with or without cisplatin.
European journal of cancer (Oxford, England : 1990) 2002;38(11):1501-11.
2002: Heike Helmbach; Monika A Kern; Evelyn Rossmann; Kristina Renz; Christine Kissel; Brigitte Gschwendt; Dirk Schadendorf
Drug resistance towards etoposide and cisplatin in human melanoma cells is associated with drug-dependent apoptosis deficiency.
The Journal of investigative dermatology 2002;118(6):923-32.
2002: Yuansheng Sun; Alice J A M Sijts; Mingxia Song; Katharina Janek; Alexander K Nussbaum; Sylvie Kral; Markus Schirle; Stefan Stevanovic; Annette Paschen; Hansjörg Schild; Peter-M Kloetzel; Dirk Schadendorf
Expression of the proteasome activator PA28 rescues the presentation of a cytotoxic T lymphocyte epitope on melanoma cells.
Cancer research 2002;62(10):2875-82.
2002: Xuan Duc Nguyen; Hermann Eichler; Antje Sucker; Udo Hofmann; Dirk Schadendorf; Harald Klüter
Collection of autologous monocytes for dendritic cell vaccination therapy in metastatic melanoma patients.
Transfusion 2002;42(4):428-32.
2002: Carmen Scheibenbogen; Yuansheng Sun; Ulrich Keilholz; Mingxia Song; Stefan Stevanovic; Anne Marie Asemissen; Dirk Nagorsen; Eckhard Thiel; Hans-Georg Rammensee; Dirk Schadendorf
Identification of known and novel immunogenic T-cell epitopes from tumor antigens recognized by peripheral blood T cells from patients responding to IL-2-based treatment.
International journal of cancer. Journal international du cancer 2002;98(3):409-14.
2002: Danila Valmori; Carmen Scheibenbogen; Valérie Dutoit; Dirk Nagorsen; Anne Marie Asemissen; Verena Rubio-Godoy; Donata Rimoldi; Philippe Guillaume; Pedro Romero; Dirk Schadendorf; Martin Lipp; Pierre-Yves Dietrich; Eckhard Thiel; Jean-Charles Cerottini; Danielle Liénard; Ulrich Keilholz
Circulating Tumor-reactive CD8(+) T cells in melanoma patients contain a CD45RA(+)CCR7(-) effector subset exerting ex vivo tumor-specific cytolytic activity.
Cancer research 2002;62(6):1743-50.
2002: Julia Poland; Dirk Schadendorf; Hermann Lage; Martina Schnölzer; Julio E Celis; Pranav Sinha
Study of therapy resistance in cancer cells with functional proteome analysis.
Clinical chemistry and laboratory medicine : CCLM / FESCC 2002;40(3):221-34.
2002: Marilisa Carsana; Gabrina Tragni; Gabriella Nicolini; Ilaria Bersani; Giorgio Parmiani; Andrea Anichini; Yuan Sheng Sun; Peter Möller; Dirk Schadendorf; Marialuisa Sensi
Comparative assessment of TCRBV diversity in T lymphocytes present in blood, metastatic lesions, and DTH sites of two melanoma patients vaccinated with an IL-7 gene-modified autologous tumor cell vaccine.
Cancer gene therapy 2002;9(3):243-53.
2002: Dirk Schadendorf
The use of histamine in cancer immunotherapy.
The Journal of investigative dermatology 2002;118(3):560-1.
2002: Dirk Schadendorf
Is there a standard for the palliative treatment of melanoma?
Onkologie 2002;25(1):74-6.
2002: Yuansheng Sun; Dirk Schadendorf
Gene-based immunotherapy of skin cancers.
Recent results in cancer research. Fortschritte der Krebsforschung. Progrès dans les recherches sur le cancer 2002;160():170-84.
2002: A Garbea; Edgar Dippel; Ralf Hildenbrand; Uwe Bleyl; Dirk Schadendorf; Sergij Goerdt
Cutaneous large B-cell lymphoma of the leg masquerading as a chronic venous ulcer.
The British journal of dermatology 2002;146(1):144-7.
2001: D Djukanovic; U Hofmann; Antje Sucker; Dirk Schadendorf
Melanoma tumour markers S100B and MIA: evaluation of stability in serum and blood upon storage and processing.
The British journal of dermatology 2001;145(6):1030-1.
2001: Dirk Schadendorf
[Tumor-specific therapy strategies in oncology].
Onkologie 2001;24 Suppl 5():56-9.
2001: Y Sun; M Song; M J Maeurer; Dirk Schadendorf
Segregation of effector mechanisms in a tumour-specific CD8+ T-cell clone correlates with CD30 expression.
Scandinavian journal of immunology 2001;54(3):314-20.
2001: Heike Helmbach; E Rossmann; Monika A Kern; Dirk Schadendorf
Drug-resistance in human melanoma.
International journal of cancer. Journal international du cancer 2001;93(5):617-22.
2001: Hermann Lage; C Perlitz; Rupert Abele; Robert Tampé; Manfred Dietel; Dirk Schadendorf; P Sinha
Enhanced expression of human ABC-transporter tap is associated with cellular resistance to mitoxantrone.
FEBS letters 2001;503(2-3):179-84.
2001: Hermann Lage; Heike Helmbach; C Grottke; Manfred Dietel; Dirk Schadendorf
DFNA5 (ICERE-1) contributes to acquired etoposide resistance in melanoma cells.
FEBS letters 2001;494(1-2):54-9.
2001: Markus Christmann; M Pick; Hermann Lage; Dirk Schadendorf; Bernd Kaina
Acquired resistance of melanoma cells to the antineoplastic agent fotemustine is caused by reactivation of the DNA repair gene MGMT.
International journal of cancer. Journal international du cancer 2001;92(1):123-9.
2001: Stefan B Eichmüller; Dirk Usener; Reinhard Dummer; A Stein; Daniela Thiel; Dirk Schadendorf
Serological detection of cutaneous T-cell lymphoma-associated antigens.
Proceedings of the National Academy of Sciences of the United States of America 2001;98(2):629-34.
2000: C Grottke; Klaus Mantwill; Manfred Dietel; Dirk Schadendorf; Hermann Lage
Identification of differentially expressed genes in human melanoma cells with acquired resistance to various antineoplastic drugs.
International journal of cancer. Journal international du cancer 2000;88(4):535-46.
2000: Anne Letsch; Ulrich Keilholz; Dirk Schadendorf; Dirk Nagorsen; Alexander Schmittel; Eckhard Thiel; Carmen Scheibenbogen
High frequencies of circulating melanoma-reactive CD8+ T cells in patients with advanced melanoma.
International journal of cancer. Journal international du cancer 2000;87(5):659-64.
2000: Pranav Sinha; S Kohl; J Fischer; Gero Hütter; M Kern; Eckart Köttgen; Manfred Dietel; Hermann Lage; Martina Schnölzer; Dirk Schadendorf
Identification of novel proteins associated with the development of chemoresistance in malignant melanoma using two-dimensional electrophoresis.
Electrophoresis 2000;21(14):3048-57.
2000: Dirk Schadendorf; F Belardelli; M Ferrantini; G Parmiani; M P Colombo
Conference on cancer vaccines.
Cancer immunology, immunotherapy : CII 2000;49(4-5):281-4.
2000: Peter Möller; H Möller; Y Sun; Tomislav Dorbic; Beate M Henz; Burghardt Wittig; Dirk Schadendorf
Increased non-major histocompatibility complex-restricted lytic activity in melanoma patients vaccinated with cytokine gene-transfected autologous tumor cells.
Cancer gene therapy 2000;7(7):976-84.
2000: D Djukanovic; U Hofmann; Antje Sucker; Werner Rittgen; Dirk Schadendorf
Comparison of S100 protein and MIA protein as serum marker for malignant melanoma.
Anticancer research 2000;20(3B):2203-7.
2000: SO Arndt; Anne B Vogt; Silva Markovic-Plese; R Martin; Gerhard Moldenhauer; A Wölpl; Y Sun; Dirk Schadendorf; Günter J Hämmerling; Harald Kropshofer
Functional HLA-DM on the surface of B cells and immature dendritic cells.
The EMBO journal 2000;19(6):1241-51.
2000: Carmen Scheibenbogen; Alexander Schmittel; Ulrich Keilholz; T Allgäuer; U Hofmann; Regina Max; Eckhard Thiel; Dirk Schadendorf
Phase 2 trial of vaccination with tyrosinase peptides and granulocyte-macrophage colony-stimulating factor in patients with metastatic melanoma.
Journal of immunotherapy (Hagerstown, Md. : 1997) 2000;23(2):275-81.
2000: Hermann Lage; Heike Helmbach; Manfred Dietel; Dirk Schadendorf
Modulation of DNA topoisomerase II activity and expression in melanoma cells with acquired drug resistance.
British journal of cancer 2000;82(2):488-91.
1999: W Nürnberg; D Tobias; F Otto; B M Henz; Dirk Schadendorf
Expression of interleukin-8 detected by in situ hybridization correlates with worse prognosis in primary cutaneous melanoma.
The Journal of pathology 1999;189(4):546-51.
1999: Y Sun; Peter Möller; Carola Berking; EM Schlüpen; M Volkenandt; Dirk Schadendorf
In vivo selective expansion of a tumour-specific cytotoxic T-cell clone derived from peripheral blood of a melanoma patient after vaccination with gene-modified autologous tumour cells.
Immunology 1999;98(4):535-40.
1999: Pranav Sinha; Gero Hütter; Eckart Köttgen; Manfred Dietel; Dirk Schadendorf; Hermann Lage
Search for novel proteins involved in the development of chemoresistance in colorectal cancer and fibrosarcoma cells in vitro using two-dimensional electrophoresis, mass spectrometry and microsequencing.
Electrophoresis 1999;20(14):2961-9.
1999: Pranav Sinha; Gero Hütter; Eckart Köttgen; Manfred Dietel; Dirk Schadendorf; Hermann Lage
Increased expression of epidermal fatty acid binding protein, cofilin, and 14-3-3-sigma (stratifin) detected by two-dimensional gel electrophoresis, mass spectrometry and microsequencing of drug-resistant human adenocarcinoma of the pancreas.
Electrophoresis 1999;20(14):2952-60.
1999: Hermann Lage; Markus Christmann; M A Kern; Manfred Dietel; M Pick; Bernd Kaina; Dirk Schadendorf
Expression of DNA repair proteins hMSH2, hMSH6, hMLH1, O6-methylguanine-DNA methyltransferase and N-methylpurine-DNA glycosylase in melanoma cells with acquired drug resistance.
International journal of cancer. Journal international du cancer 1999;80(5):744-50.
1999: Michelle Nessling; Monika A Kern; Dirk Schadendorf; Peter Lichter
Association of genomic imbalances with resistance to therapeutic drugs in human melanoma cell lines.
Cytogenetics and cell genetics 1999;87(3-4):286-90.
1998: Pranav Sinha; Gero Hütter; Eckart Köttgen; Manfred Dietel; Dirk Schadendorf; Hermann Lage
Increased expression of annexin I and thioredoxin detected by two-dimensional gel electrophoresis of drug resistant human stomach cancer cells.
Journal of biochemical and biophysical methods 1998;37(3):105-16.
1998: S Seiter; Dirk Schadendorf; Wolfgang Tilgen; Margot Zöller
CD44 variant isoform expression in a variety of skin-associated autoimmune diseases.
Clinical immunology and immunopathology 1998;89(1):79-93.
1998: Peter Möller; Y Sun; Tomislav Dorbic; S Alijagic; A Makki; K Jurgovsky; Matthias Schroff; Beate M Henz; Burghardt Wittig; Dirk Schadendorf
Vaccination with IL-7 gene-modified autologous melanoma cells can enhance the anti-melanoma lytic activity in peripheral blood of patients with a good clinical performance status: a clinical phase I study.
British journal of cancer 1998;77(11):1907-16.
1998: Y Sun; K Jurgovsky; Peter Möller; S Alijagic; Tomislav Dorbic; J Georgieva; Burghardt Wittig; Dirk Schadendorf
Vaccination with IL-12 gene-modified autologous melanoma cells: preclinical results and a first clinical phase I study.
Gene therapy 1998;5(4):481-90.
1998: Peter Möller; Burghardt Wittig; Dirk Schadendorf
Intratumoral adoptive immunotherapy with tumor infiltrating lymphocytes (TIL) in a melanoma patient leading to regression of local tumor mass. A case report.
Anticancer research 1998;18(2B):1237-41.
1998: Frank O Nestle; S Alijagic; Michel Gilliet; Y Sun; S Grabbe; Reinhard Dummer; Günter Burg; Dirk Schadendorf
Vaccination of melanoma patients with peptide- or tumor lysate-pulsed dendritic cells.
Nature medicine 1998;4(3):328-32.
1997: Monika A Kern; Heike Helmbach; M Artuc; D Karmann; K Jurgovsky; Dirk Schadendorf
Human melanoma cell lines selected in vitro displaying various levels of drug resistance against cisplatin, fotemustine, vindesine or etoposide: modulation of proto-oncogene expression.
Anticancer research 1997;17(6D):4359-70.
1997: S Finke; B Trojaneck; Peter Möller; Dirk Schadendorf; Andreas Neubauer; Dieter Huhn; Ingo G H Schmidt-Wolf
Increase of cytotoxic sensitivity of primary human melanoma cells transfected with the interleukin-7 gene to autologous and allogeneic immunologic effector cells.
Cancer gene therapy 1997;4(4):260-8.
1997: Ulrich Keilholz; S H Goey; C J Punt; Thomas M Proebstle; R Salzmann; Carmen Scheibenbogen; Dirk Schadendorf; D Liénard; A Enk; R Dummer; B Hantich; A M Geueke; A M Eggermont
Interferon alfa-2a and interleukin-2 with or without cisplatin in metastatic melanoma: a randomized trial of the European Organization for Research and Treatment of Cancer Melanoma Cooperative Group.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1997;15(7):2579-88.
1996: Dirk Schadendorf; Monika A Kern; Metin Artuc; H L Pahl; T Rosenbach; I Fichtner; W Nürnberg; S Stüting; E von Stebut; M Worm; A Makki; K Jurgovsky; Gerhard Kolde; Beate M Henz
Treatment of melanoma cells with the synthetic retinoid CD437 induces apoptosis via activation of AP-1 in vitro, and causes growth inhibition in xenografts in vivo.
The Journal of cell biology 1996;135(6 Pt 2):1889-98.
1996: Dirk Schadendorf; I Fichtner; A Makki; S Alijagic; M Küpper; U Mrowietz; Beate M Henz
Metastatic potential of human melanoma cells in nude mice--characterisation of phenotype, cytokine secretion and tumour-associated antigens.
British journal of cancer 1996;74(2):194-9.
1996: Peter Möller; M Böhm; B M Czarnetszki; Dirk Schadendorf
Interleukin-7. Biology and implications for dermatology.
Experimental dermatology 1996;5(3):129-37.
1996: S Seiter; Wolfgang Tilgen; K Herrmann; Dirk Schadendorf; E Patzelt; Peter Möller; Margot Zöller
Expression of CD44 splice variants in human skin and epidermal tumours.
Virchows Archiv : an international journal of pathology 1996;428(3):141-9.
1996: S Seiter; Dirk Schadendorf; K Herrmann; M Schneider; M Rösel; R Arch; Wolfgang Tilgen; Margot Zöller
Expression of CD44 variant isoforms in malignant melanoma.
Clinical cancer research : an official journal of the American Association for Cancer Research 1996;2(3):447-56.
1996: Dirk Schadendorf; S Diehl; Torsten Zuberbier; C Schadendorf; Beate M Henz
Quantitative detection of soluble adhesion molecules in sera of melanoma patients correlates with clinical stage.
Dermatology (Basel, Switzerland) 1996;192(2):89-93.
1995: Dirk Schadendorf; A Makki; C Stahr; A van Dyck; Reinhard Wanner; George L Scheffer; Marcel J Flens; R Scheper; Beate M Henz
Membrane transport proteins associated with drug resistance expressed in human melanoma.
The American journal of pathology 1995;147(6):1545-52.
1995: S Alijagic; Peter Möller; Metin Artuc; K Jurgovsky; B M Czarnetzki; Dirk Schadendorf
Dendritic cells generated from peripheral blood transfected with human tyrosinase induce specific T cell activation.
European journal of immunology 1995;25(11):3100-7.
1995: Metin Artuc; W Nürnberg; M Platzer; B M Czarnetzki; Dirk Schadendorf
Differential promoter activity in benign and malignant human cells of skin origin.
Experimental dermatology 1995;4(5):317-21.
1995: Dirk Schadendorf; Torsten Zuberbier; S Diehl; C Schadendorf; B M Czarnetzki
Serum manganese superoxide dismutase is a new tumour marker for malignant melanoma.
Melanoma research 1995;5(5):351-3.
1995: W Nürnberg; Metin Artuc; M Nawrath; J Lovric; S Stüting; Karin Moelling; B M Czarnetzki; Dirk Schadendorf
Human c-myb is expressed in cervical carcinomas and transactivates the HPV-16 promoter.
Cancer research 1995;55(19):4432-7.
1995: Dirk Schadendorf; B M Czarnetzki; Burghardt Wittig
Interleukin-7, interleukin-12, and GM-CSF gene transfer in patients with metastatic melanoma.
Journal of molecular medicine (Berlin, Germany) 1995;73(9):473-7.
1995: Metin Artuc; W Nürnberg; B M Czarnetzki; Dirk Schadendorf
Characterization of gene regulatory elements for selective gene expression in human melanoma cells.
Biochemical and biophysical research communications 1995;213(2):699-705.
1995: Dirk Schadendorf; K Jurgovsky; C M Kohlmus; B M Czarnetzki
Glutathione and related enzymes in tumor progression and metastases of human melanoma.
The Journal of investigative dermatology 1995;105(1):109-12.
1995: W Nürnberg; Metin Artuc; G Vorbrueggen; F Kalkbrenner; Karin Moelling; B M Czarnetzki; Dirk Schadendorf
Nuclear proto-oncogene products transactivate the human papillomavirus type 16 promoter.
British journal of cancer 1995;71(5):1018-24.
1995: Dirk Schadendorf; R Herfordt; B M Czarnetzki
P-glycoprotein expression in primary and metastatic malignant melanoma.
The British journal of dermatology 1995;132(4):551-5.
1995: W Nürnberg; B M Czarnetzki; Dirk Schadendorf
DIG-labeled RNA in situ hybridization without coverslipping.
BioTechniques 1995;18(3):406-8.
1995: Dirk Schadendorf; J Heidel; C Gawlik; Ludwig Suter; B M Czarnetzki
Association with clinical outcome of expression of VLA-4 in primary cutaneous malignant melanoma as well as P-selectin and E-selectin on intratumoral vessels.
Journal of the National Cancer Institute 1995;87(5):366-71.
1995: W Nürnberg; Norbert Haas; Dirk Schadendorf; B M Czarnetzki
Interleukin-6 expression in the skin of patients with lupus erythematosus.
Experimental dermatology 1995;4(1):52-7.
1995: M Worm; A Makki; Edgar Dippel; B M Czarnetzki; Dirk Schadendorf
Interferon-gamma downregulates epidermal growth factor receptors on human melanoma cells.
Experimental dermatology 1995;4(1):30-5.
1995: Edgar Dippel; Norbert Haas; Jürgen Grabbe; Dirk Schadendorf; K Hamann; B M Czarnetzki
Expression of the c-kit receptor in hypomelanosis: a comparative study between piebaldism, naevus depigmentosus and vitiligo.
The British journal of dermatology 1995;132(2):182-9.
1995: Dirk Schadendorf; C Kohlmus; C Gawlik; Ludwig Suter; B M Czarnetzki
Mast cells in melanocytic tumours.
Archives of dermatological research 1995;287(5):452-6.
1995: Dirk Schadendorf; M Worm; K Jurgovsky; Edgar Dippel; U Reichert; B M Czarnetzki
Effects of various synthetic retinoids on proliferation and immunophenotype of human melanoma cells in vitro.
Recent results in cancer research. Fortschritte der Krebsforschung. Progrès dans les recherches sur le cancer 1995;139():183-93.
1994: Bernd Algermissen; F Bauer; Dirk Schadendorf; J D Kropp; B M Czarnetzki
Analysis of mast cell subpopulations (MCT, MCTC) in cutaneous inflammation using novel enzyme-histochemical staining techniques.
Experimental dermatology 1994;3(6):290-7.
1994: Dirk Schadendorf; K Jurgovsky; M Worm; B M Czarnetzki
In vitro sensitivity of human melanoma cells to chemotherapeutic agents and interferons.
Melanoma research 1994;4(4):243-9.
1994: M Böhm; P Möller; U Kalbfleisch; M Worm; B M Czarnetzki; Dirk Schadendorf
Lysis of allogeneic and autologous melanoma cells by IL-7-induced lymphokine-activated killer cells.
British journal of cancer 1994;70(1):54-9.
1994: Dirk Schadendorf; M Böhm; P Möller; T Grünewald; B M Czarnetzki
Interleukin-7 induces differential lymphokine-activated killer cell activity against human melanoma cells, keratinocytes, and endothelial cells.
The Journal of investigative dermatology 1994;102(6):838-42.
1994: Dirk Schadendorf; M Worm; Bernd Algermissen; C M Kohlmus; B M Czarnetzki
Chemosensitivity testing of human malignant melanoma. A retrospective analysis of clinical response and in vitro drug sensitivity.
Cancer 1994;73(1):103-8.
1993: Dirk Schadendorf; Norbert Haas; M Worm; H Ostmeier; C Kohlmus; Joachim Gottschalk; Bernd Algermissen; G Jautzke; B M Czarnetzki
Amelanotic malignant melanoma presenting as malignant schwannoma.
The British journal of dermatology 1993;129(5):609-14.
1993: Dirk Schadendorf; Norbert Haas; F Nürnberger; B M Czarnetzki
[Recurrent nodular panniculitis in alpha 1-antitrypsin deficiency. Successful dapsone therapy].
Der Hautarzt; Zeitschrift für Dermatologie, Venerologie, und verwandte Gebiete 1993;44(10):653-7.
1993: M Worm; U Reichert; Edgar Dippel; B M Czarnetzki; Dirk Schadendorf
Expression of growth factor receptors on human melanoma cells: comparison of modulating effects of interferons and retinoids.
Experimental dermatology 1993;2(5):217-23.
1993: A Möller; Undine Lippert; D Lessmann; Gerhard Kolde; K Hamann; Pia Welker; Dirk Schadendorf; T Rosenbach; Thomas Luger; B M Czarnetzki
Human mast cells produce IL-8.
Journal of immunology (Baltimore, Md. : 1950) 1993;151(6):3261-6.
1993: Dirk Schadendorf; A Möller; Bernd Algermissen; M Worm; Michael Sticherling; B M Czarnetzki
IL-8 produced by human malignant melanoma cells in vitro is an essential autocrine growth factor.
Journal of immunology (Baltimore, Md. : 1950) 1993;151(5):2667-75.
1993: Dirk Schadendorf; C Gawlik; U Haney; H Ostmeier; Ludwig Suter; B M Czarnetzki
Tumour progression and metastatic behaviour in vivo correlates with integrin expression on melanocytic tumours.
The Journal of pathology 1993;170(4):429-34.
1993: Dirk Schadendorf; Bernd Algermissen; K Hamann; Matthias Riewald; F Nürnberger; B M Czarnetzki
Acute monoblastic leukemia with skin nodules in an adult.
Journal of the American Academy of Dermatology 1993;28(5 Pt 2):884-8.
1993: Dirk Schadendorf; M Worm; B M Czarnetzki
Brain metastases of metastatic malignant melanoma: response to DTIC and interferon-gamma.
Journal of neuro-oncology 1993;16(1):77-9.
1993: Dirk Schadendorf; Norbert Haas; H Ostmeier; B M Czarnetzki
Primary leiomyosarcoma of the skin. A histological and immunohistochemical analysis.
Acta dermato-venereologica 1993;73(2):143-5.
1993: M Worm; Dirk Schadendorf; B M Czarnetzki
Responsiveness to interferon treatment of human melanoma cells correlates to immunophenotype.
Melanoma research 1993;3(1):29-33.
1993: Dirk Schadendorf; M Worm; B M Czarnetzki
Determination of granulocyte/macrophage-colony-stimulating factor secretion by human melanoma cells and its effects on human melanoma cell proliferation.
Journal of cancer research and clinical oncology 1993;119(8):501-3.
1992: Dirk Schadendorf; Norbert Haas; H Ostmeier; B Brechtel; A Voges; F Nürnberger; B M Czarnetzki
[Early detection for prevention of malignant melanoma in Berlin].
Der Hautarzt; Zeitschrift für Dermatologie, Venerologie, und verwandte Gebiete 1992;43(1):52-3.
1991: Dirk Schadendorf; B M Czarnetzki
Gene amplification by polymerase chain reaction in dermatology.
The Journal of investigative dermatology 1991;97(5):751-5.
1991: Dirk Schadendorf; K H Tiedemann; N Haas; B M Czarnetzki
Detection of human papillomaviruses in paraffin-embedded condylomata acuminata--comparison of immunohistochemistry, in situ hybridization, and polymerase chain reaction.
The Journal of investigative dermatology 1991;97(3):549-54.